<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">


<meta name="wpd_version" content="0.2">
<meta name="wpd_baseurl" content="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra022812">
<meta name="wpd_url" content="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra022812">
<meta name="wpd_date" content="2013-04-28T14:00Z">
<script src="auth013.js" type="text/javascript"></script>

<script src="g" async="" type="text/javascript"></script><script type="text/javascript" src="monetate.js"></script>






<title>Novel Therapies Based on Mechanisms of HIV-1 Cell Entry — NEJM</title>
<meta name="description" content="Review Article from The New England Journal of Medicine — Novel Therapies Based on Mechanisms of HIV-1 Cell Entry">

<meta name="pageType" content="Article">
<meta name="evt-pageType" content="Article">








   <meta property="og:title" content="Novel Therapies Based on Mechanisms of HIV-1 Cell Entry — NEJM">
   <meta property="og:description" content="Review Article from The New England Journal of Medicine — Novel Therapies Based on Mechanisms of HIV-1 Cell Entry">
   <meta property="og:type" content="article">
   <meta property="og:image" content="http://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.348.issue-22/nejmra022812/production/images/small/nejmra022812_f1.gif">
   <meta name="twitter:card" content="summary">
   <meta name="twitter:site" content="@NEJM">



















	
	    <meta name="evt-doiPage" content="10.1056/NEJMra022812">
	
	
	
	    <meta name="evt-dt" content="2003-05-29">
	
	
	
	    <meta name="evt-ageContent" content="6Months-1990">
	
	
	
	    <meta name="evt-free" content="no">
	

	
		
				<meta name="evt-artView" content="full">
				
			
	
			
	
		<link rel="canonical" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra022812">
		
	
















<meta name="sessionEvt-individual" content="">
<meta name="sessionEvt-idGUID" content="">
<meta name="sessionEvt-freeCntry" content="">
<meta name="sessionEvt-instId" content="1452137">
<meta name="sessionEvt-audSegment" content="">
<meta name="sessionEvt-prodCode" content="">
<meta name="sessionEvt-nejmSource" content="">
<meta name="sessionEvt-offers" content="N-institution-currentArticles">






	








<!-- Load CSS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-css-global -->
<!-- placeholder id=null, description=N-config-css-ads -->

<script type="text/javascript" src="jquery.js"></script>
<script type="text/javascript" src="siteEditor.js"></script>
<script type="text/javascript" src="jquery.cookie.js"></script>
<script type="text/javascript" src="jquery.bbq.js"></script>
<script type="text/javascript" src="mmsEventMappings.js"></script>
<script type="text/javascript" src="mmsEvents.js"></script>
<script type="text/javascript" src="script.js"></script>
<script type="text/javascript" src="mmsFilterBanks.js"></script>
<script type="text/javascript" src="mmsMenus.js"></script>
<script type="text/javascript" src="mmsClassData.js"></script>
<script type="text/javascript" src="mmsAds.js"></script>
<script type="text/javascript" src="mmsCarousels.js"></script>
<script type="text/javascript" src="mmsUtilities.js"></script>
<script type="text/javascript" src="mmsTabPanel.js"></script>
<script type="text/javascript" src="mmsViews.js"></script>
<script type="text/javascript" src="mmsBoxy.js"></script>
<script type="text/javascript" src="jquery.form.js"></script>
<script type="text/javascript" src="swfobject.js"></script>
<script type="text/javascript" src="jquery.dimensions.js"></script>
<script type="text/javascript" src="jquery.cluetip.js"></script>
<script type="text/javascript" src="jquery.highlight.js"></script>
<script type="text/javascript" src="jquery.jcarousel.js"></script>
<script type="text/javascript" src="jquery-ui-1.7.2.custom.min.js"></script>
<script type="text/javascript" src="mmsLayers.js"></script>
<script type="text/javascript" src="mmsAddThis.js"></script>

<!--[if IE]><script language="javascript" type="text/javascript" src="http://cdn.nejm.org.libgate.library.nuigalway.ie/5.2/js/lib/excanvas.min.js"></script><![endif]-->






<!--[if lte IE 6]><script type="text/javascript" src="http://cdn.nejm.org.libgate.library.nuigalway.ie/5.2/js/DD_belatedPNG.js"></script><![endif]-->
<script type="text/javascript" src="ntpagetag.js"></script><script src="unica_eluminate.js" type="text/javascript"></script>

<script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script>

<!-- Load JS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-js-global-top -->

<script async="" src="795826938" type="text/javascript"></script><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><div id="_atssh" style="visibility: hidden; height: 1px; width: 1px; position: absolute; z-index: 100000;"><iframe src="NEJMra022812_1.html" style="height: 1px; width: 1px; position: absolute; z-index: 100000; border: 0px none; left: 0px; top: 0px;" title="AddThis utility frame" id="_atssh292"></iframe></div><script src="core078.js" type="text/javascript"></script>
<link rel="stylesheet" type="text/css" href="NEJMra022812.css" media="all">
</head>
<body class="article">

<div id="dic_bubble" class="selection_bubble fontSize13 noSelect" style="z-index: 9999; border: 1px solid rgb(74, 174, 222); visibility: hidden;"></div><noscript>

<img src="http://pt000185.unica.com/ntpagetag.gif?site=nejm&js=0" height="1" width="1" border="0" hspace="0" vspace="0" alt=" ">
</noscript>





<script type="text/javascript">

   
    var servicesURL="http://imc.nejm.org/ExamService/ExamService.asmx";
</script>


















<script type="text/javascript">

    var CM8Server = "web.checkm8.com";
    var CM8Cat = "mms.nej.articles";
    var CM8Profile = "pharma=no&articlecat=review";
</script>
<script type="text/javascript" language="JavaScript" src="cm8adam_1_ajax.js"></script>



<!--[if lte IE 6]><div class="ie6and7" id="ie6"><![endif]-->
<!--[if IE 7]><div class="ie6and7" id="ie7"><![endif]-->
<!--[if IE 8]><div id="ie8"><![endif]-->















<div id="topAdBar">
<div class="bannerAd">
<div class="inner">














<div id="CM8ShowAd1369749603390" title="Topbanner" class="Topbanner CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/Topbanner"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369749603390&amp;format=Topbanner" border="0" alt="Advertisement" /></a></noscript>

</div></div>
</div>
</div>






<div style="margin-top: 30px;" align="center">
    <!-- placeholder id=null, description=N-ad-global-top --><div style="background: none repeat ; 0% rgb(255, 255, 255); padding: 0px; width: 970px; height: 20px; margin: 0px auto 10px;" align="left"><p style="font: 11px/15px arial,sans-serif; color: rgb(51, 51, 51);">Learn how NEJM.org uses cookies at the <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3528&amp;url=%2Fpage%2Fabout-nejm%2Fcookie-information&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Cookie Information</a> page.</p></div>
</div>











<script type="text/javascript">

    $(document).ready(function() {
        $("#lnkSignOut").click(function(){
            $.cookie("redirectUri",null, {path: '/', domain: '.nejm.org'});
        });
    })
</script>

<div id="authInfo">

    <!-- placeholder id=null, description=N-ad-global-top-left -->
        <!-- topLeftAniv -->
            <div class="topLeftAniv">
             
            </div>
        <!-- /topLeftAniv -->
    

    <ul>
        
        
                
                        <li class="status firstChild">Welcome</li>
                    
            

        
        <!-- placeholder id=null, description=N-ad-authstring -->
            <li class="authOptions">
            <span class="renewSubscribe"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Drenew%26promo%3DONFLRNA2&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="renew">Renew</a>, <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26promo%3DONFQN1A2&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="subscribe">Subscribe</a> or <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Dregister%26promo%3DONFLNAR3&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="createAccount">Create Account</a></span>
            </li>
        

        
        
                <li class="signin lastChild">
                    
                            <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showLogin?uri=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812" class="viewType-Layer viewClass-WideLayer signin-header">

                                
                                        
                                    
                                Sign In
                            </a>
                        
                </li>
            

    </ul>
</div>






<div id="header" class="withAd">
	<h1><a href="http://www.nejm.org.libgate.library.nuigalway.ie/">The New England Journal of Medicine</a></h1>
    
        <!-- placeholder id=null, description=N-ad-header-1 -->
            <div class="ad"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3942&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26url%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra022812%26promo%3DONFQRN01&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102"><img src="SubscribeDefault_iPadEdition_280x83-2.jpg">
</a></div>
        
    
</div>






	

<div style="position: relative;" id="topNav">
<ul>
<li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/">Home</a></li>
<li class="menu dropDownTrigger-articles"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-article-index">Articles &amp; Multimedia</a></li>
<li class="menu dropDownTrigger-issueArchive"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-index">Issues</a></li>
<li class="menu dropDownTrigger-topics"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-specialties">Specialties &amp; Topics</a></li>
<li class="menu authors dropDownTrigger-authors"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">For Authors</a></li>
<li class="menu cmeButton lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/continuing-medical-education">CME</a></li>
</ul>
    <form action="http://www.nejm.org.libgate.library.nuigalway.ie/search?pageType=search" class="search" method="get"><fieldset>
    <div style="position: absolute; left: 654px; top: 23px; width: 225px; visibility: hidden; z-index: 99999999;" class="autocomplete"></div><input id="sli_search_1" class="text" name="q" value="Keyword, Title, Author, or Citation" size="15" maxlength="450" autocomplete="off" type="text">	
	<input class="searchSubmit" value="Search" src="search_icon.gif" type="image">
    <input disabled="" name="asug" value="" type="hidden">
    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-search" class="more advSearch">Advanced<br>Search</a>
    </fieldset></form>
</div>

<div id="main">

    <div id="content">

    
    




    <a name="articleTop" rel="10.1056/NEJMra022812"></a><p class="articleType">Review Article</p><p class="seriesTitle">Mechanisms of Disease</p><h1>Novel Therapies Based on Mechanisms of HIV-1 Cell Entry</h1><p class="authors">J. Michael Kilby, M.D., and Joseph J. Eron, M.D.</p><p class="citationLine"><span class="citation">N Engl J Med 2003;  348:2228-2238</span><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/348/22/">May 29, 2003</a><span class="doi">DOI:  10.1056/NEJMra022812</span></p><!--DiscussionPollOpenDateReplacer--><!-- share -->
<div class="share addthis_toolbox no-pad-bot" addthis:url="http://www.nejm.org/doi/full/10.1056/NEJMra022812">
    <div class="cols">
        <div class="col"><span class="label">Share:</span></div>
        <div class="col">
            <a href="#" title="Facebook" class="addthis_button_facebook at300b"><span class="icon add facebook"></span></a>
        </div>
        <div class="col">
            <a href="#" title="Tweet" class="addthis_button_twitter at300b"><span class="icon add twitter"></span></a>
        </div>
        <div class="col">
            <a title="Google+" target="_top" href="http://www.addthis.com/bookmark.php?v=300&amp;winname=addthis&amp;pub=ra-4ddfaaf00b1e6fbf&amp;source=tbx-300&amp;lng=en-US&amp;s=google_plusone_share&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;title=Novel%20Therapies%20Based%20on%20Mechanisms%20of%20HIV-1%20Cell%20Entry%20%E2%80%94%20NEJM&amp;ate=AT-ra-4ddfaaf00b1e6fbf/-/-/51a4b86b9b8c08b0/2&amp;frommenu=1&amp;uid=51a4b86bbe32f10b&amp;ct=1&amp;ui_cobrand=NEJM.org&amp;pre=http%3A%2F%2Fdx.doi.org%2F10.1056%252FNEJMra022812&amp;tt=0&amp;captcha_provider=nucaptcha" class="addthis_button_google_plusone_share at300b"><span class="icon add google"></span></a>
        </div>
        <div class="col">
            <a title="Linkedin" target="_top" href="http://www.addthis.com/bookmark.php?v=300&amp;winname=addthis&amp;pub=ra-4ddfaaf00b1e6fbf&amp;source=tbx-300&amp;lng=en-US&amp;s=linkedin&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;title=Novel%20Therapies%20Based%20on%20Mechanisms%20of%20HIV-1%20Cell%20Entry%20%E2%80%94%20NEJM&amp;ate=AT-ra-4ddfaaf00b1e6fbf/-/-/51a4b86b9b8c08b0/3&amp;frommenu=1&amp;uid=51a4b86b497b959a&amp;shortener=bitly&amp;bitly.login=nejm&amp;bitly.apiKey=R_644f2c9aae1c9bcb164b6f24392c94f4&amp;ct=1&amp;ui_cobrand=NEJM.org&amp;pre=http%3A%2F%2Fdx.doi.org%2F10.1056%252FNEJMra022812&amp;tt=0&amp;captcha_provider=nucaptcha" class="addthis_button_linkedin at300b"><span class="icon add linkedin"></span></a>
        </div>
        <div class="col">
            <a class="addthis_button"><span class="icon add addmore"></span></a>
        </div>
    </div>
<div class="atclear"></div></div>
<!-- /share --><dl class="articleTabs tabPanel lastChild"><dt class="active article firstChild sideBySide" id="articleTab">Article</dt><dt class="references sideBySide inactive" id="referencesTab">References</dt><dt class="citedby sideBySide inactive" id="citedbyTab">Citing Articles <span>(89) </span></dt><!--DiscussionReplacer_Tab_--><dt class="letters sideBySide inactive" id="lettersTab">Letters</dt><dd style="display: block;" id="article"><div class="section"> <p>Infection with human immunodeficiency virus type 1 (HIV-1), the retrovirus that causes the acquired immunodeficiency syndrome (AIDS), is one of the leading causes of death worldwide. All currently available antiretroviral agents inhibit essential HIV-1 enzymes — either the reverse transcriptase or the protease (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f01">Figure 1</a><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f01"><img src="nejmra022812_f1.gif" alt=""></a><span class="figureCaption">The Life Cycle of Human Immunodeficiency Virus Type 1 (HIV-1), Showing Potential Targets for Antiretroviral Therapy.</span></span>). Recent advances have markedly improved the outcome for many patients who receive these classes of antiretroviral drugs. However, the success of current therapy is limited by the emergence of drug-resistant viruses, the necessity of sustained adherence to complex regimens, and the potential for toxic effects. Novel classes of safe and effective agents with a low risk of cross-resistance with other antiretroviral drugs are needed.</p> <p>Targeting viral entry may have advantages over the inhibition of steps in the viral life cycle after the cell has been infected. A better understanding of how HIV-1 binds to and enters cells has prompted a reappraisal of previous attempts to block viral entry and an evaluation of new approaches (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=t01">Table 1</a><span class="table"><span class="figureTitle">Table 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=t01"><img src="nejmra022812_t1.gif" alt=""></a><span class="figureCaption">Examples of Inhibitors of HIV-1 Cell Entry in Development.</span></span>). In this article, we outline the steps involved in viral attachment and entry, provide an update on agents under development that have been designed to inhibit each of these steps, and consider the prospects of these compounds in the treatment of human immunodeficiency virus (HIV) infection.</p> </div><div class="section"> <h3 id="articleHIV-1 Binding and Entry">HIV-1 Binding and Entry</h3> <div class="subSection"> <h3 id="articleEarly Characterization of the Viral Envelope and CD4+ T-Cell Tropism">Early Characterization of the Viral Envelope and CD4+ T-Cell Tropism</h3> <p>The initial characterization of HIV-1 centered on its tropism for mature human helper T lymphocytes, which express the CD4 (or T4) surface protein (also expressed on monocytes, dendritic cells, and brain microglia).<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1-4</a></span> Molecular studies demonstrated that, like other retroviruses, the HIV-1 particle is surrounded by a lipid bilayer, derived from the host cell and studded with viral glycoproteins (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f02">Figure 2</a><span class="fig"><span class="figureTitle">Figure 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f02"><img src="nejmra022812_f2.gif" alt=""></a><span class="figureCaption">HIV-1–Binding Events and Potential Sites of Action for Various Viral-Entry Inhibitors.</span></span>). The infectivity of HIV requires the surface glycoprotein subunit (gp120) and the transmembrane glycoprotein subunit (gp41) of gp160, a viral precursor protein. The two subunits are cleaved from gp160 by host-cell proteases and then reassembled as oligomeric structures (trimers) on the viral membrane (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03">Figure 3A</a><span class="fig"><span class="figureTitle">Figure 3</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03"><img src="nejmra022812_f3.gif" alt=""></a><span class="figureCaption">Proposed Model of the gp41-Mediated Membrane-Fusion Step, Showing Sites of Action for Fusion Inhibitors in Development.</span></span>).<span class="ref"><a href="#ref5" class="showRefLayer" rel="#refLayer">5,6</a></span> </p> <p>The amino acid sequence of gp120 contains five variable regions (V1 through V5), alternating with more conserved regions; the variable regions tend to be exposed on the viral surface.<span class="ref"><a href="#ref7" class="showRefLayer" rel="#refLayer">7,8</a></span> Noncontiguous regions of the gp120 molecule come together to form the CD4 binding site, and small deletions or substitutions in either CD4 or conserved regions of gp120 disrupt the binding of the virus.<span class="ref"><a href="#ref9" class="showRefLayer" rel="#refLayer">9-11</a></span> </p> <p>The design of inhibitors of viral entry must take into account the three-dimensional structure and the variability in the sequence of the intact wild-type HIV-1 envelope, rather than the linear sequences of denatured proteins or the envelopes of laboratory-adapted strains of HIV-1, which do not reliably predict the in vivo activity of investigational agents that block viral entry.</p> </div> <div class="subSection"> <h3 id="articleThe Search for Entry Cofactors">The Search for Entry Cofactors</h3> <p>Because CD4 alone is insufficient to permit the entry of HIV-1, it has long been suspected that additional receptors or other factors are required. Although most HIV-1 isolates successfully infect primary helper T cells, individual viral isolates have a range of tropisms (for example, in vitro, some preferentially infect macrophages over T-cell lines) and cause varying degrees of cell fusion (formation of syncytia or multinucleated giant cells) in T-cell lines. Amino acid residues within conserved V3-loop sites of gp120 were known to affect membrane fusion,<span class="ref"><a href="#ref12" class="showRefLayer" rel="#refLayer">12,13</a></span> but the basis of the differences in tropism was until recently poorly understood. Important clues to the “coreceptor” mystery arose from the discovery that β-chemokines (macrophage inflammatory proteins 1α and 1β [MIP-1α and MIP-1β], as well as RANTES [regulated upon activation normal T-cell expressed and secreted]), which are chemotactic cytokines produced by macrophages, activated T cells, and natural killer cells, suppress the replication of some strains of HIV-1.<span class="ref"><a href="#ref14" class="showRefLayer" rel="#refLayer">14</a></span> </p> </div> <div class="subSection"> <h3 id="articleChemokine Coreceptors (Cc Chemokine Receptor 5 and CXC Chemokine Receptor 4)">Chemokine Coreceptors (Cc Chemokine Receptor 5 and CXC Chemokine Receptor 4)</h3> <p>After the seminal discovery by Feng and colleagues that a G-protein–coupled chemokine receptor, CXC chemokine receptor 4 (CXCR4), was the key to cellular entry for viruses that grow well in cultured T-cell lines (X4 viruses),<span class="ref"><a href="#ref15" class="showRefLayer" rel="#refLayer">15</a></span> several groups of researchers rapidly confirmed that chemokine receptors were the missing link in our understanding of HIV-1 entry (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f02">Figure 2</a>). The expression of CXCR4 made otherwise impenetrable CD4+ cell lines susceptible to productive HIV-1 infection. CC chemokine receptor 5 (CCR5), a β-chemokine receptor with a seven-transmembrane-protein structure similar to that of CXCR4, was found to serve as a coreceptor for non–syncytium-inducing or macrophage-tropic HIV-1 (R5 viruses).<span class="ref"><a href="#ref16" class="showRefLayer" rel="#refLayer">16,17</a></span> Chemokine receptors are the primary binding sites for many related retroviruses, and HIV-1 can be genetically modified to allow CD4-independent cell entry,<span class="ref"><a href="#ref18" class="showRefLayer" rel="#refLayer">18</a></span> suggesting that CXCR4 and CCR5 are the primordial receptors, rather than just cofactors.<span class="ref"><a href="#ref19" class="showRefLayer" rel="#refLayer">19</a></span> </p> <p>HIV-1 isolates of the R5 type have been implicated in most cases of sexually transmitted HIV infection, whereas X4 viruses, which replicate best in T-cell lines, often predominate in the later stages of HIV disease and may be associated with rapid progression to AIDS and death.<span class="ref"><a href="#ref20" class="showRefLayer" rel="#refLayer">20,21</a></span> Clinical isolates may contain mixtures of R5 and X4 viruses, and some individual viral strains (R5X4, or dual-tropic viruses) can use either the CXCR4 (X4-virus) or CCR5 (R5-virus) receptor.<span class="ref"><a href="#ref22" class="showRefLayer" rel="#refLayer">22</a></span> As previous experiments have suggested, V3-loop amino acid sequences in gp120 are major determinants of chemokine-receptor affinity.<span class="ref"><a href="#ref23" class="showRefLayer" rel="#refLayer">23,24</a></span> Although other chemokine receptors (CC chemokine receptors 2, 3, and 8, BOB, and others) can facilitate the entry of specific HIV-1 variants in vitro, all clinical isolates of HIV-1 use CCR5, CXCR4, or both for entry.<span class="ref"><a href="#ref25" class="showRefLayer" rel="#refLayer">25</a></span> </p> <p>Naturally occurring host defects in CCR5 expression have demonstrated the clinical significance of these receptors. A homozygous deletion that prevents CCR5 expression occurs disproportionately among persons who are frequently exposed to HIV-1 but who nonetheless remain uninfected.<span class="ref"><a href="#ref26" class="showRefLayer" rel="#refLayer">26</a></span> Heterozygous or partial mutation of a gene responsible for CCR5 expression on the cell surface does not block infection but does provide some protection from disease progression.<span class="ref"><a href="#ref27" class="showRefLayer" rel="#refLayer">27</a></span> Rare cases of infection in persons with a homozygous deletion of the gene responsible for CCR5 expression appear to be caused by X4 viruses.<span class="ref"><a href="#ref28" class="showRefLayer" rel="#refLayer">28</a></span> </p> </div> <div class="subSection"> <h3 id="articleMembrane Fusion">Membrane Fusion</h3> <p>The final step in viral entry, the fusion of the viral envelope with the cell membrane, is mediated by gp41. The molecular sequence of gp41 includes “heptad-repeat” regions (HR1 and HR2), reflecting the presence of periodic hydrophobic regions found in α-helical “coiled-coil” structures.<span class="ref"><a href="#ref29" class="showRefLayer" rel="#refLayer">29,30</a></span> Mutations in the HR regions interfere with the fusion property of gp41.<span class="ref"><a href="#ref31" class="showRefLayer" rel="#refLayer">31</a></span> </p> <p>A model of gp41-mediated membrane fusion analogous to the “spring-loaded” mechanism of influenzavirus has been proposed. After influenzavirus attaches to a target cell and enters the acid-rich endosome, the conformation of the hemagglutinin protein changes, shifting a “fusion peptide” into favorable position for the mediation of fusion.<span class="ref"><a href="#ref32" class="showRefLayer" rel="#refLayer">32</a></span> The model predicts that the gp120–gp41 trimer holds each gp41 in a high-energy configuration, with the fusion peptide pointed inward, toward the viral surface (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03">Figure 3A</a>). The binding of gp120 to CD4 and chemokine receptors is thought to release gp41 from this configuration, causing the fusion peptide to spring outward toward the cell membrane (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03">Figure 3B</a>). Still in their trimeric association, the HR1 regions then fold over into the hydrophobic groove formed by the three corresponding HR2 regions, forming a stable six-helix bundle, thus bringing viral and cell membranes into proximity for fusion and entry (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03">Figure 3C</a>).<span class="ref"><a href="#ref33" class="showRefLayer" rel="#refLayer">33</a></span> </p> </div> <div class="subSection"> <h3 id="articleCrystallizing the Dynamic Roles of the Viral Envelope Proteins">Crystallizing the Dynamic Roles of the Viral Envelope Proteins</h3> <p>Partial x-ray crystallization of the HIV-1 glycoproteins, in complex with receptors, sheds light on the three-dimensional interactions between viral and host components during binding and entry.<span class="ref"><a href="#ref19" class="showRefLayer" rel="#refLayer">19</a></span> This imaging of the complexes has confirmed the sequential conformational changes that follow the binding of the virus to CD4 and chemokine receptors and has suggested the occurrence of several interdependent steps in the process of viral entry.</p> </div> </div><div class="section"> </div><div class="section"> <h3 id="articleInhibition of Viral Entry">Inhibition of Viral Entry</h3> <div class="subSection"> <h3 id="articleInhibiting the Interaction of GP120 with the CD4 Molecule">Inhibiting the Interaction of GP120 with the CD4 Molecule</h3> <p>Initial attempts to block HIV entry focused on the interaction between gp120 and CD4. Recombinant soluble CD4 (rsCD4), which was developed as a viral-attachment decoy, demonstrated potent inhibition of HIV-1 infection in vitro.<span class="ref"><a href="#ref34" class="showRefLayer" rel="#refLayer">34,35</a></span> In the clinical setting, however, rsCD4 had negligible activity except at very high doses.<span class="ref"><a href="#ref36" class="showRefLayer" rel="#refLayer">36-39</a></span> A chimeric molecule consisting of recombinant CD4 and gamma globulin had an extended half-life yet had little or no activity when administered with zidovudine.<span class="ref"><a href="#ref40" class="showRefLayer" rel="#refLayer">40</a></span> Despite these failures, new inhibitors of interactions between gp120 and CD4 continue to be pursued.</p> <p>PRO 542, a hybrid tetramer, contains CD4 receptor domains within an IgG2 backbone and acts as a decoy for gp120 binding. It is active in vitro against diverse strains of HIV-1, including clinical isolates.<span class="ref"><a href="#ref41" class="showRefLayer" rel="#refLayer">41</a></span> PRO 542 must be administered parenterally but has a half-life in plasma of more than three days. In pilot studies, the compound was well tolerated and there was evidence of antiviral activity in adults<span class="ref"><a href="#ref42" class="showRefLayer" rel="#refLayer">42</a></span> and children.<span class="ref"><a href="#ref43" class="showRefLayer" rel="#refLayer">43</a></span> </p> <p>Monoclonal anti-CD4 antibodies can also block the interaction between gp120 and CD4; some of these monoclonal antibodies can inhibit the replication of multiple subtypes of HIV-1 in vitro.<span class="ref"><a href="#ref44" class="showRefLayer" rel="#refLayer">44</a></span> Although anti-CD4 antibodies may have immunosuppressive effects,<span class="ref"><a href="#ref45" class="showRefLayer" rel="#refLayer">45,46</a></span> a recent report on a humanized anti-CD4 antibody called TNX-355 demonstrated no serious adverse events in the short term and no CD4-cell depletion. This dose-escalation trial showed clinically significant reductions in the viral load (of &gt;1.0 log<sub>10</sub> copies of HIV-1 RNA per milliliter) two to three weeks after a single intravenous dose of 10 to 25 mg per kilogram of body weight.<span class="ref"><a href="#ref47" class="showRefLayer" rel="#refLayer">47</a></span> </p> <p>Certain small molecules may competitively and reversibly inhibit viral entry by binding gp120 and blocking the gp120–CD4 interaction.<span class="ref"><a href="#ref48" class="showRefLayer" rel="#refLayer">48</a></span> A lead compound of this type (BMS-806) demonstrated potent HIV-1 inhibition in vitro, but activity varied among different subtypes (clades) of HIV-1 and even within the same clade. Mutations in the region of gp120 that binds to CD4 cause resistance to BMS-806, supporting the proposed mechanism of action.<span class="ref"><a href="#ref49" class="showRefLayer" rel="#refLayer">49</a></span> </p> </div> <div class="subSection"> <h3 id="articleNonspecific Interference with Attachment">Nonspecific Interference with Attachment</h3> <p>Dextran sulfate and other polyanions can inhibit the replication of HIV-1 in vitro.<span class="ref"><a href="#ref50" class="showRefLayer" rel="#refLayer">50</a></span> Originally attributed to nonspecific, charge-mediated interference with gp120–CD4 interactions, the effect of dextran sulfate has been linked more recently to its ability to attach to the V3 loop of X4 or R5X4 viruses, thus blocking the binding of gp120 to coreceptors.<span class="ref"><a href="#ref51" class="showRefLayer" rel="#refLayer">51,52</a></span> Dextran sulfate inhibits the replication of X4 isolates but may enhance R5 infections in vitro.<span class="ref"><a href="#ref53" class="showRefLayer" rel="#refLayer">53</a></span> Clinically, intravenous dextran sulfate was toxic and in some cases appeared to increase viral replication.<span class="ref"><a href="#ref54" class="showRefLayer" rel="#refLayer">54</a></span> </p> <p>PRO 2000 is a naphthalene polyanion that binds to CD4 but not to gp120<span class="ref"><a href="#ref55" class="showRefLayer" rel="#refLayer">55</a></span>; it is currently in clinical trials as a topical microbicide.<span class="ref"><a href="#ref56" class="showRefLayer" rel="#refLayer">56</a></span> Cyanovirin-N, another topical compound with an active ingredient derived from blue-green algae, may interfere with several receptor-binding functions of gp120 simultaneously.<span class="ref"><a href="#ref57" class="showRefLayer" rel="#refLayer">57</a></span> </p> </div> <div class="subSection"> <h3 id="articleBlocking Chemokine-Receptor Binding">Blocking Chemokine-Receptor Binding</h3> <p>Several agents that bind the CCR5 and CXCR4 receptors and block HIV-1 replication in vitro are in development.<span class="ref"><a href="#ref14" class="showRefLayer" rel="#refLayer">14,58-61</a></span> CCR5 may be a desirable target, because persons without CCR5 expression on the surface of cells are relatively resistant to HIV-1 infection and have no obvious immunologic deficiencies. However, the role of CCR5 in inflammatory and immune responses is not fully understood and may vary in different clinical settings. Because X4 variants are linked with a rapid decline in the number of CD4 cells,<span class="ref"><a href="#ref20" class="showRefLayer" rel="#refLayer">20,21</a></span> it is also potentially a concern that CCR5 inhibitors may exert a selection pressure favoring CXCR4-tropic viruses.</p> <p>The natural ligands for CCR5 — the β-chemokines MIP 1-α, MIP 1-β, and RANTES — inhibit HIV-1 replication in vitro. A series of small-molecule β-chemokine antagonists and monoclonal antibodies have potent in vitro activity (a 50 percent inhibitory concentration [IC<sub>50</sub>] of less than 10 nM) against R5 variants, have no activity against X4 viruses, and act synergistically with approved antiretroviral drugs.<span class="ref"><a href="#ref62" class="showRefLayer" rel="#refLayer">62-65</a></span> Several compounds are now in clinical development. In a short-term pilot study, one such compound, SCH-C, reduced the mean plasma viral load by a factor of about three, although the effect varied from subject to subject.<span class="ref"><a href="#ref66" class="showRefLayer" rel="#refLayer">66</a></span> Selection of SCH-C–resistant HIV-1 in vitro has been observed without a switch from CCR5 to CXCR4 coreceptor usage.<span class="ref"><a href="#ref67" class="showRefLayer" rel="#refLayer">67</a></span> </p> <p>Because CXCR4 occurs on a wider range of types of cells than CCR5, there is concern about potential adverse effects of blocking this receptor. Indeed, CXCR4-knockout mice have fatal congenital defects (including abnormal B-cell development and multiple malformations).<span class="ref"><a href="#ref68" class="showRefLayer" rel="#refLayer">68</a></span> Several CXCR4 antagonists (cationic bicyclams) with in vitro activity have been developed,<span class="ref"><a href="#ref69" class="showRefLayer" rel="#refLayer">69-71</a></span> but it has been difficult to administer them, and their in vivo activity has been limited. One pilot study of a CXCR4 antagonist involving 40 HIV-infected subjects demonstrated selective pressure against X4 variants, but a response in the plasma viral load was observed in only one subject.<span class="ref"><a href="#ref72" class="showRefLayer" rel="#refLayer">72</a></span> Amino acid changes in gp120 (some in and around the V3 loop) that confer resistance to CXCR4 antagonists have been described.<span class="ref"><a href="#ref73" class="showRefLayer" rel="#refLayer">73</a></span> The α-defensins, recently described endogenous HIV-1–inhibitory factors, are small cationic proteins that act predominantly against X4 variants<span class="ref"><a href="#ref74" class="showRefLayer" rel="#refLayer">74</a></span>; at least part of this antiviral activity may be related to blocking the entry of the virus.</p> </div> <div class="subSection"> <h3 id="articleBlocking the Fusion of Virus with the Cell Membrane">Blocking the Fusion of Virus with the Cell Membrane</h3> <p>Synthetic peptides that mimic HR2 segments of gp41 and probably block fusion by binding competitively to the hydrophobic groove formed by intertwined HR1 regions when gp41 is in its extended conformation (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra022812&amp;iid=f03">Figure 3</a>) have significant antiretroviral effects in vitro.<span class="ref"><a href="#ref29" class="showRefLayer" rel="#refLayer">29-31</a></span> Two peptides, T-20 and T-1249, are currently being studied in clinical trials. Several groups of investigators have demonstrated that other compounds in preclinical development — smaller peptides as well as a “five-helix” protein<span class="ref"><a href="#ref75" class="showRefLayer" rel="#refLayer">75-77</a></span> — inhibit the replication of HIV-1 by related mechanisms.</p> </div> <div class="subSection"> <h3 id="articleT-20 (Enfuvirtide)">T-20 (Enfuvirtide)</h3> <p>Enfuvirtide (T-20), a 36-amino-acid peptide derived from the HR2 sequence of a laboratory strain of HIV-1, has broad activity against X4, R5, and dual-tropic variants of HIV-1<span class="ref"><a href="#ref78" class="showRefLayer" rel="#refLayer">78</a></span> and is furthest along in clinical development. Oral treatment with this large peptide is not feasible. The initial clinical study of intravenous enfuvirtide monotherapy demonstrated potent antiretroviral effects without clinically significant short-term toxic effects.<span class="ref"><a href="#ref79" class="showRefLayer" rel="#refLayer">79</a></span> Further studies were undertaken to evaluate the use of enfuvirtide by subcutaneous injection. In a 28-day phase 2 study involving 78 HIV-infected adults in whom conventional regimens had failed, enfuvirtide was delivered by continuous subcutaneous infusion with the use of an insulin pump or by twice-daily subcutaneous injection.<span class="ref"><a href="#ref80" class="showRefLayer" rel="#refLayer">80</a></span> Dose-related decreases in the viral load were observed with both methods of administration, but continuous subcutaneous infusion was hampered by technical difficulties. The largest reductions in viral load (mean reduction, 1.6 log<sub>10</sub> copies of HIV-1 RNA per milliliter) were observed in the group that received twice-daily injections of 100 mg of enfuvirtide. Viral-load rebound during therapy was noted in some subjects, and drug resistance was demonstrated in viruses from some of these subjects.<span class="ref"><a href="#ref81" class="showRefLayer" rel="#refLayer">81</a></span> </p> <p>Longer-term activity and tolerability appeared favorable in 70 subjects who had previously been involved in short-term clinical trials, who were then offered further open-label therapy with enfuvirtide (50 mg twice daily by subcutaneous injection).<span class="ref"><a href="#ref82" class="showRefLayer" rel="#refLayer">82</a></span> A randomized, open-label trial involving patients who had received protease inhibitors but had not had a clinical response to them suggested that switching to a salvage regimen containing a nonnucleoside reverse-transcriptase inhibitor plus enfuvirtide was more effective than the same salvage regimen without enfuvirtide.<span class="ref"><a href="#ref83" class="showRefLayer" rel="#refLayer">83</a></span> These results were similar to, or better than, those of other trials involving salvage regimens for subjects who had been treated with multiple antiretroviral regimens, but the limited size of these studies and their designs preclude definitive conclusions.</p> <p>The results of two parallel phase 3 studies of enfuvirtide in patients with extensive previous treatment, one (T-20 vs. Optimized Regimen Only Study 1 [TORO 1])<span class="ref"><a href="#ref84" class="showRefLayer" rel="#refLayer">84</a></span> involving 491 subjects in North America and South America and the other (T-20 vs. Optimized Regimen Only Study 2 [TORO 2])<span class="ref"><a href="#ref85" class="showRefLayer" rel="#refLayer">85</a></span> involving 504 subjects in Europe and Australia, are published in this issue of the <em>Journal</em>. All participants underwent genotypic and phenotypic resistance testing to assist with the individualized selection of the best available antiretroviral regimen (the optimized background regimen), which consisted of three to five drugs, and then were randomly assigned in a 2:1 ratio to receive the optimized background regimen plus subcutaneous enfuvirtide or the optimized background regimen alone. At week 24, the mean reductions in viral load in these patients with relatively advanced and treatment-resistant disease were significantly greater among enfuvirtide recipients than among controls.</p> <p>The most common adverse events in all studies of subcutaneous enfuvirtide have been injection-site reactions, which are typically mild but occur in the majority of patients. These reactions usually result in pruritic subcutaneous nodules, although larger painful inflammatory masses are occasionally observed. In the phase 3 trials,<span class="ref"><a href="#ref84" class="showRefLayer" rel="#refLayer">84,85</a></span> self-administration of enfuvirtide was generally successful; approximately 3 percent of the patients discontinued treatment because of local reactions. A complex process of synthesis is required to produce enfuvirtide, but methods are being streamlined, and the drug has recently received approval from the Food and Drug Administration.</p> </div> <div class="subSection"> <h3 id="articleT-1249">T-1249</h3> <p>The second peptide inhibitor of fusion that is now in development, T-1249, binds to a region partially overlapping with the region to which enfuvirtide binds but extending into a “deep-pocket” region of HR1 that is important for the formation of the six-helix structure required for fusion.<span class="ref"><a href="#ref86" class="showRefLayer" rel="#refLayer">86</a></span> T-1249 has been studied in a 14-day phase 1–2 trial involving 115 HIV-1–infected subjects. Subjects received T-1249 alone at a total daily dose ranging from 6.25 to 200 mg, with some groups receiving once-daily injections and others twice-daily injections.<span class="ref"><a href="#ref87" class="showRefLayer" rel="#refLayer">87</a></span> The largest median declines in plasma HIV-1 RNA levels (2.0 log<sub>10</sub> copies per milliliter) were observed in subjects receiving 150 to 200 mg once daily. Three serious adverse events thought to be related to T-1249 were observed.</p> </div> <div class="subSection"> <h3 id="articleResistance to Enfuvirtide and T-1249">Resistance to Enfuvirtide and T-1249</h3> <p>Analyses of HIV-1 from patients in the middle-dose groups of the original phase 1 trial of enfuvirtide demonstrated a rapid evolution of changes in the HR1 coding region, which correlated with resistance to the drug.<span class="ref"><a href="#ref88" class="showRefLayer" rel="#refLayer">88</a></span> The mutations cluster around a specific gp41 region,<span class="ref"><a href="#ref89" class="showRefLayer" rel="#refLayer">89,90</a></span> supporting the putative mechanism of action of enfuvirtide. Two amino acid changes in this region may lead to decreases by a factor of 100 in susceptibility. Most variants that are resistant to enfuvirtide maintain susceptibility to T-1249 in vitro.<span class="ref"><a href="#ref81" class="showRefLayer" rel="#refLayer">81</a></span> Viruses containing mutations that confer resistance to enfuvirtide may have disadvantages of replication capacity (decreased “viral fitness”) in the absence of selection pressure from the drug, as compared with wild-type virus.<span class="ref"><a href="#ref91" class="showRefLayer" rel="#refLayer">91</a></span> Recently, antiviral activity of T-1249 was demonstrated in subjects with prolonged previous exposure to enfuvirtide and documented enfuvirtide-resistant virus.<span class="ref"><a href="#ref92" class="showRefLayer" rel="#refLayer">92</a></span> </p> </div> </div><div class="section"> </div><div class="section"> <h3 id="articleFuture Considerations">Future Considerations</h3> <p>A new, diverse class of compounds designed or selected to inhibit the entry of HIV-1 into host cells is approaching clinical application. Early clinical experience with some of these compounds has been favorable, and toxic effects or drug-resistance patterns that overlap with those of currently available therapies have not been observed. Randomized clinical trials have recently demonstrated a benefit when a fusion inhibitor, enfuvirtide, is given as part of a salvage regimen for patients with drug-resistant HIV-1 who currently have limited therapeutic options.</p> <p>As with all available antiretroviral agents, the clinical activity of viral-entry inhibitors will be limited by selection for drug-resistant viral variants unless the compounds can be used together with other effective drugs. Because dual-tropic virus or mixed populations of viruses may be present within the same host, CCR5 and CXCR4 inhibitors may have a greater likelihood of clinical effectiveness if they can be safely administered in combination. The availability of chemokine receptors modulates the susceptibility to membrane-fusion inhibitors in some in vitro assays<span class="ref"><a href="#ref90" class="showRefLayer" rel="#refLayer">90,93,94</a></span>; however, there is no evidence thus far that this observation will have clinically significant implications.<span class="ref"><a href="#ref95" class="showRefLayer" rel="#refLayer">95</a></span> Several groups have demonstrated potent synergism between viral-entry inhibitors when various combinations of agents directed at the gp120–CD4 interaction (PRO 542), chemokine-receptor antagonists, and peptide-fusion inhibitors are evaluated in vitro.<span class="ref"><a href="#ref96" class="showRefLayer" rel="#refLayer">96-98</a></span> </p> <p>Observations regarding the range of susceptibility of different viral strains under different assay conditions and regarding the different degrees of synergism between agents that block viral entry may have similar pathogenetic explanations: factors that impede the initial steps toward entry, especially interactions with CCR5 or CXCR4, may increase the window of opportunity for peptide inhibitors such as enfuvirtide to interfere with gp41-mediated fusion.<span class="ref"><a href="#ref94" class="showRefLayer" rel="#refLayer">94</a></span> These findings suggest that there may be good prospects for potent combinations of entry inhibitors, just as HIV-1 protease inhibitors or reverse-transcriptase inhibitors are administered together today.</p> </div><div class="section"> </div><div class="section section-hr"></div><div class="section section-back"> <p>Supported by grants (AI50410 and AI27767) to the Centers for AIDS Research at the University of North Carolina and the University of Alabama, Birmingham; by a grant (5MO1 RR00032-38) to the Pittman General Clinical Research Center at the University of Alabama, Birmingham; and by grants (AI41530-05 and AI32775-07) from the National Institutes of Health.</p> <p>We are indebted to Michael S. Saag, M.D., for constant support and guidance over the years; and to Eric Hunter, Ph.D., for expert assistance with figures and mechanistic explanations.</p></div><div class="section section-back"><div class="sourceInfo"><h3>Source Information</h3><p>From the Department of Medicine, University of Alabama, Birmingham (J.M.K.); and the Department of Medicine, University of North Carolina, Chapel Hill (J.J.E.).</p><p>Address reprint requests to Dr. Kilby at 908 20th St. S., UAB, Birmingham, AL 35294-2050, or at <a class="email" href="mailto:mkilby@uab.edu">mkilby@uab.edu</a>.</p></div></div><div class="section section-back lastChild"></div></dd><dd style="display: none;" id="references"><div class="section"><h3>References</h3><ol class="striped"><a name="ref1"></a><li class="odd" id="refItem1"><p class="number">1</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Barre-Sinoussi F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chermann JC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rey F</contrib>, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). <span class="NLM_source">Science</span> 1983;220:868-871<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.6189183" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1983QP69600068" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=6189183" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref2"></a><li class="even" id="refItem2"><p class="number">2</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallo RC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sarin PS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gelmann EP</contrib>, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). <span class="NLM_source">Science</span> 1983;220:865-867<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.6601823" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1983QP69600067" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=6601823" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref3"></a><li class="odd" id="refItem3"><p class="number">3</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Klatzmann D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Champagne E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chamaret S</contrib>, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. <span class="NLM_source">Nature</span> 1984;312:767-768<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F312767a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1984TW94000062" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=6083454" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref4"></a><li class="even" id="refItem4"><p class="number">4</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dalgleish AG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Beverley PCL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clapham PR</contrib>, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. <span class="NLM_source">Nature</span> 1984;312:763-767<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r004&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F312763a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r004&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1984TW94000061" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r004&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=6096719" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref5"></a><li class="odd" id="refItem5"><p class="number">5</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Earl PL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Doms RW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moss B</contrib>. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 1990;87:648-652<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.87.2.648" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1990CK37800030" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2300552" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref6"></a><li class="even" id="refItem6"><p class="number">6</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Weiss CD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Levy JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">White JM</contrib>. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. <span class="NLM_source">J Virol</span> 1990;64:5674-5677<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r006&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1990EE04800060" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r006&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2214033" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref7"></a><li class="odd" id="refItem7"><p class="number">7</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wyatt R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sullivan N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Thali M</contrib>, et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. <span class="NLM_source">J Virol</span> 1993;67:4557-4565<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r007&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1993LM27200013" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r007&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8331723" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref8"></a><li class="even" id="refItem8"><p class="number">8</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moore JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sattentau QJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wyatt R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sodroski J</contrib>. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. <span class="NLM_source">J Virol</span> 1994;68:469-484<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r008&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1994MW25100052" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r008&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7504741" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref9"></a><li class="odd" id="refItem9"><p class="number">9</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Peterson A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Seed B</contrib>. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. <span class="NLM_source">Cell</span> 1988;54:65-72<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2F0092-8674%2888%2990180-8" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1988P139300008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2454749" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref10"></a><li class="even" id="refItem10"><p class="number">10</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lasky LA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nakamura G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Smith DH</contrib>, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. <span class="NLM_source">Cell</span> 1987;50:975-985<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2F0092-8674%2887%2990524-1" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1987K058100017" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2441877" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref11"></a><li class="odd" id="refItem11"><p class="number">11</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kowalski M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Potz J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Basiripour L</contrib>, et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. <span class="NLM_source">Science</span> 1987;237:1351-1355<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r011&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.3629244" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r011&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1987J924400027" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r011&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=3629244" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref12"></a><li class="even" id="refItem12"><p class="number">12</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Skinner MA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Langlois AJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McDanal CB</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McDougal JS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bolognesi DP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matthews TJ</contrib>. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. <span class="NLM_source">J Virol</span> 1988;62:4195-4200<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r012&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1988Q489900035" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r012&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2845130" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref13"></a><li class="odd" id="refItem13"><p class="number">13</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Freed EO</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Myers DJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Risser R</contrib>. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. <span class="NLM_source">J Virol</span> 1991;65:190-194<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r013&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1991EM92600023" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r013&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=1985197" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref14"></a><li class="even" id="refItem14"><p class="number">14</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cocchi F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">DeVico AL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Garzino-Demo A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Arya SK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallo RC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lusso P</contrib>. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. <span class="NLM_source">Science</span> 1995;270:1811-1815<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.270.5243.1811" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1995TK47600043" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8525373" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref15"></a><li class="odd" id="refItem15"><p class="number">15</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Feng Y</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Broder CC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kennedy PE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Berger EA</contrib>. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. <span class="NLM_source">Science</span> 1996;272:872-877<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.272.5263.872" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996UK75700059" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8629022" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref16"></a><li class="even" id="refItem16"><p class="number">16</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dragic T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Litwin V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Allaway GP</contrib>, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. <span class="NLM_source">Nature</span> 1996;381:667-673<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r016&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F381667a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r016&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996UR97900042" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r016&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8649512" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref17"></a><li class="odd" id="refItem17"><p class="number">17</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Deng H</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Liu R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ellmeier W</contrib>, et al. Identification of a major co-receptor for primary isolates of HIV-1. <span class="NLM_source">Nature</span> 1996;381:661-666<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F381661a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996UR97900041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8649511" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref18"></a><li class="even" id="refItem18"><p class="number">18</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hoxie JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">LaBranche CC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Endres MJ</contrib>, et al. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. <span class="NLM_source">J Reprod Immunol</span> 1998;41:197-211<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2FS0165-0378%2898%2900059-X" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000077946200016" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10213311" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref19"></a><li class="odd" id="refItem19"><p class="number">19</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wyatt R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sodroski J</contrib>. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. <span class="NLM_source">Science</span> 1998;280:1884-1888<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.280.5371.1884" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000074323800046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9632381" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref20"></a><li class="even" id="refItem20"><p class="number">20</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Koot M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Keet IP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Vos AH</contrib>, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. <span class="NLM_source">Ann Intern Med</span> 1993;118:681-688<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r020&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1993KY50200004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r020&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8096374" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref21"></a><li class="odd" id="refItem21"><p class="number">21</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Richman DD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bozzette SA</contrib>. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. <span class="NLM_source">J Infect Dis</span> 1994;169:968-974<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1093%2Finfdis%2F169.5.968" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1994NW34600004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7909549" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref22"></a><li class="even" id="refItem22"><p class="number">22</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Singh A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Collman RG</contrib>. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. <span class="NLM_source">J Virol</span> 2000;74:10229-10235<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.74.21.10229-10235.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000089819900048" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11024154" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref23"></a><li class="odd" id="refItem23"><p class="number">23</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Choe H</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Farzan M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sun Y</contrib>, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. <span class="NLM_source">Cell</span> 1996;85:1135-1148<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2FS0092-8674%2800%2981313-6" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996UV48400019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8674119" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref24"></a><li class="even" id="refItem24"><p class="number">24</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cocchi F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">DeVico AL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Garzino-Demo A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cara A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallo RC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lusso P</contrib>. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. <span class="NLM_source">Nat Med</span> 1996;2:1244-1247<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2Fnm1196-1244" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996VQ10100041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8898753" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref25"></a><li class="odd" id="refItem25"><p class="number">25</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clapham PR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McNight A</contrib>. Cell surface receptors, virus entry and tropism of primate lentiviruses. <span class="NLM_source">J Gen Virol</span> 2002;83:1809-1829<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r025&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000176989900001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r025&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12124446" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref26"></a><li class="even" id="refItem26"><p class="number">26</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Liu R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Paxton WA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Choe S</contrib>, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. <span class="NLM_source">Cell</span> 1996;86:367-377<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r026&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2FS0092-8674%2800%2980110-5" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r026&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996VC30900005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r026&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8756719" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref27"></a><li class="odd" id="refItem27"><p class="number">27</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dean M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Carrington M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Winkler C</contrib>, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. <span class="NLM_source">Science</span> 1996;273:1856-1862[Erratum, Science 1996;274:1069.]<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r027&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.273.5283.1856" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r027&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996VJ71300044" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r027&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8791590" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref28"></a><li class="even" id="refItem28"><p class="number">28</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Michael NL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nelson JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">KewalRamani VN</contrib>, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. <span class="NLM_source">J Virol</span> 1998;72:6040-6047<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r028&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000074160500083" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r028&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9621067" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref29"></a><li class="odd" id="refItem29"><p class="number">29</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallaher WR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ball JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Garry RF</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Griffin MC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Montelaro RC</contrib>. A general model of the transmembrane proteins of HIV and other retroviruses. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 1989;5:431-440<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r029&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1089%2Faid.1989.5.431" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r029&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1989AL73300008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r029&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2788443" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref30"></a><li class="even" id="refItem30"><p class="number">30</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Delwart EL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mosialos G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gilmore T</contrib>. Retroviral envelope glycoproteins contain a “leucine zipper“-like repeat. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 1990;6:703-706<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r030&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1089%2Faid.1990.6.703" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r030&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1990DP85900001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r030&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2364015" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref31"></a><li class="odd" id="refItem31"><p class="number">31</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dubay JW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Roberts SJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Brody B</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hunter E</contrib>. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. <span class="NLM_source">J Virol</span> 1992;66:4748-4756<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r031&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1992JF09800017" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r031&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=1629954" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref32"></a><li class="even" id="refItem32"><p class="number">32</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Carr C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kim PS</contrib>. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. <span class="NLM_source">Cell</span> 1993;73:823-832<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2F0092-8674%2893%2990260-W" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1993LD83000019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8500173" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref33"></a><li class="odd" id="refItem33"><p class="number">33</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chen CH</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matthews TJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McDanal CB</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bolognesi DP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Greenberg ML</contrib>. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. <span class="NLM_source">J Virol</span> 1995;69:3771-3777<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r033&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1995QX93100060" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r033&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7538176" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref34"></a><li class="even" id="refItem34"><p class="number">34</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Fisher RA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bertonis JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meier W</contrib>, et al. HIV infection is blocked in vitro by recombinant soluble CD4. <span class="NLM_source">Nature</span> 1988;331:76-78<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F331076a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1988L550500058" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2829022" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref35"></a><li class="odd" id="refItem35"><p class="number">35</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hussey RE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Richardson NE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kowalski M</contrib>, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. <span class="NLM_source">Nature</span> 1988;331:78-81<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F331078a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1988L550500059" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2829023" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref36"></a><li class="even" id="refItem36"><p class="number">36</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schooley RT</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merigan TC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gaut P</contrib>, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: a phase I-II escalating dosage trial. <span class="NLM_source">Ann Intern Med</span> 1990;112:247-253<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r036&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1990CN55400004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r036&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2297203" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref37"></a><li class="odd" id="refItem37"><p class="number">37</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schacker T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Collier AC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Coombs R</contrib>, et al. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. <span class="NLM_source">J Acquir Immune Defic Syndr Hum Retrovirol</span> 1995;9:145-152<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r037&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7749791" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref38"></a><li class="even" id="refItem38"><p class="number">38</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">O'Brien WA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chen IS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ho DD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Daar ES</contrib>. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. <span class="NLM_source">J Virol</span> 1992;66:3125-3130<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r038&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1992HP81700064" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r038&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=1373203" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref39"></a><li class="odd" id="refItem39"><p class="number">39</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moore JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McKeating JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Huang YX</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ashkenazi A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ho DD</contrib>. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. <span class="NLM_source">J Virol</span> 1992;66:235-243<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r039&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1992GU97100029" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r039&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=1727487" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref40"></a><li class="even" id="refItem40"><p class="number">40</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meng T-C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Fischl MA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cheeseman SH</contrib>, et al. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. <span class="NLM_source">J Acquir Immune Defic Syndr Hum Retrovirol</span> 1995;8:152-160<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r040&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7834398" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref41"></a><li class="odd" id="refItem41"><p class="number">41</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trkola A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pomales AB</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Yuan H</contrib>, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. <span class="NLM_source">J Virol</span> 1995;69:6609-6617<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r041&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1995RZ10000001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r041&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7474069" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref42"></a><li class="even" id="refItem42"><p class="number">42</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Jacobson JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lowy I</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Fletcher CV</contrib>, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. <span class="NLM_source">J Infect Dis</span> 2000;182:326-329<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1086%2F315698" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000088522300044" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10882617" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref43"></a><li class="odd" id="refItem43"><p class="number">43</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shearer WT</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Israel RJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Starr S</contrib>, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. <span class="NLM_source">J Infect Dis</span> 2000;182:1774-1779<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1086%2F317622" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000165596100027" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11069253" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref44"></a><li class="even" id="refItem44"><p class="number">44</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shearer MH</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Timanus DK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Benton PA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lee DR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kennedy RC</contrib>. Cross-clade inhibition of human immunodeficiency virus type 1 primary isolates by monoclonal anti-CD4. <span class="NLM_source">J Infect Dis</span> 1998;177:1727-1729<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1086%2F517432" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000073771500041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9607858" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref45"></a><li class="odd" id="refItem45"><p class="number">45</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moreland LW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bucy RP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Koopman WJ</contrib>. Regeneration of T cells after chemotherapy. <span class="NLM_source">N Engl J Med</span> 1995;332:1651-1652<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r045&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1995RC19200026" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r045&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7753155" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref46"></a><li class="even" id="refItem46"><p class="number">46</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wofsy D</contrib>. Treatment of murine lupus with anti-CD4 monoclonal antibodies. <span class="NLM_source">Immunol Ser</span> 1993;59:221-236<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r046&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8096400" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref47"></a><li class="odd" id="refItem47"><p class="number">47</p><p class="content">Kuritzkes DR, Jacobson JM, Powderly WG, et al. Safety and preliminary anti-HIV activity of an anti-CD4 mAb (TNX-355; formerly Hu5A8) in HIV-infected patients. In: Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2003:62. abstract.<br></p></li><a name="ref48"></a><li class="even" id="refItem48"><p class="number">48</p><p class="content">Lin P-F, Guo K, Fridell R, Ho H-T, Yamanaka G, Colonno R. Identification and characterization of a novel inhibitor of HIV-1 entry. II. Mechanism of action. In: Programs and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:56. abstract.<br></p></li><a name="ref49"></a><li class="odd" id="refItem49"><p class="number">49</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lin P-F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gong YF</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rose B</contrib>, et al. Generation and characterization of HIV-1 variants resistant to BMS 806, a novel HIV-1 entry inhibitor. <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl 1:S8-S8 abstract.<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r049&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000177401300007" onclick="newWindow(this.href);return false">Web of Science</a></p></li><a name="ref50"></a><li class="even" id="refItem50"><p class="number">50</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mitsuya H</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Looney DJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kuno S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ueno R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wong-Staal F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Broder S</contrib>. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. <span class="NLM_source">Science</span> 1988;240:646-649<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.2452480" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1988N126500031" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=2452480" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref51"></a><li class="odd" id="refItem51"><p class="number">51</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moulard M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lortat-Jacob H</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mondor I</contrib>, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. <span class="NLM_source">J Virol</span> 2000;74:1948-1960<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r051&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.74.4.1948-1960.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r051&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000084958000041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r051&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10644368" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref52"></a><li class="even" id="refItem52"><p class="number">52</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Este JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schols D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">De Vreese K</contrib>, et al. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. <span class="NLM_source">Mol Pharmacol</span> 1997;52:98-104<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r052&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1997XK16900014" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r052&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9224818" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref53"></a><li class="odd" id="refItem53"><p class="number">53</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meylan P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kornbluth RS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zbinden I</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Richman DD</contrib>. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. <span class="NLM_source">Antimicrob Agents Chemother</span> 1994;38:2910-2916<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r053&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1994PU60300039" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r053&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=7695283" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref54"></a><li class="even" id="refItem54"><p class="number">54</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Flexner C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Barditch-Crovo PA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kornhauser DM</contrib>, et al. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency infection. <span class="NLM_source">Antimicrob Agents Chemother</span> 1991;35:2544-2550<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r054&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1991GT89000017" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r054&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=1810188" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref55"></a><li class="odd" id="refItem55"><p class="number">55</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rusconi S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moonis M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merrill DP</contrib>, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. <span class="NLM_source">Antimicrob Agents Chemother</span> 1996;40:234-236<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r055&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996TN21300046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r055&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8787913" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref56"></a><li class="even" id="refItem56"><p class="number">56</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Van Damme L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wright A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Depraetere K</contrib>, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. <span class="NLM_source">Sex Transm Infect</span> 2000;76:126-130<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1136%2Fsti.76.2.126" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000087012800012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10858715" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref57"></a><li class="odd" id="refItem57"><p class="number">57</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mori T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boyd MR</contrib>. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. <span class="NLM_source">Antimicrob Agents Chemother</span> 2001;45:664-672<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FAAC.45.3.664-672.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000167134800003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11181340" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref58"></a><li class="even" id="refItem58"><p class="number">58</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dragic T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trkola A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Thompson DA</contrib>, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2000;97:5639-5644<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.090576697" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000086998500113" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10779565" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref59"></a><li class="odd" id="refItem59"><p class="number">59</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rusconi S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">La Seta Catamancio S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Citterio P</contrib>, et al. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. <span class="NLM_source">J Virol</span> 2000;74:9328-9332<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.74.19.9328-9332.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000089244300063" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10982382" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref60"></a><li class="even" id="refItem60"><p class="number">60</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Simmons G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clapham PR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Picard L</contrib>. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. <span class="NLM_source">Science</span> 1997;276:276-279<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.276.5310.276" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1997WT92500052" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9092481" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref61"></a><li class="odd" id="refItem61"><p class="number">61</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cairns JS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">D'Souza MP</contrib>. Chemokines and HIV-1 second receptors: the therapeutic connection. <span class="NLM_source">Nat Med</span> 1998;4:563-568<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2Fnm0598-563" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000073399900027" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9585229" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref62"></a><li class="even" id="refItem62"><p class="number">62</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mosier DE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Picchio GR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gulizia RJ</contrib>, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. <span class="NLM_source">J Virol</span> 1999;73:3544-3550<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r062&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000079701100005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r062&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10196243" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref63"></a><li class="odd" id="refItem63"><p class="number">63</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Strizki JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Xu S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wagner NE</contrib>, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2001;98:12718-12723<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.221375398" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000171806100077" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11606733" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref64"></a><li class="even" id="refItem64"><p class="number">64</p><p class="content">Reyes G. Development of CCR5 antagonists as a new class of anti-HIV therapeutic. In: Programs and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:285. abstract.<br></p></li><a name="ref65"></a><li class="odd" id="refItem65"><p class="number">65</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trkola A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ketas TJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nagashima KA</contrib>, et al. Potent broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. <span class="NLM_source">J Virol</span> 2001;75:579-588<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r065&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.75.2.579-588.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r065&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000166015000003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r065&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11134270" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref66"></a><li class="even" id="refItem66"><p class="number">66</p><p class="content">Reynes J, Rouzier R, Kanouni T, et al. Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. In: Programs and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2002:53. abstract.<br></p></li><a name="ref67"></a><li class="odd" id="refItem67"><p class="number">67</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trkola A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kuhmann SE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Strizki JM</contrib>, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2002;99:395-400<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.012519099" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000173233300071" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11782552" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref68"></a><li class="even" id="refItem68"><p class="number">68</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nagasawa T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hirota S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Tachibana K</contrib>, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. <span class="NLM_source">Nature</span> 1996;382:635-638<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r068&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F382635a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r068&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996VC30300055" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r068&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8757135" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref69"></a><li class="odd" id="refItem69"><p class="number">69</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Doranz BJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Filion LG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Diaz-Mitoma F</contrib>, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 2001;17:475-486<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1089%2F08892220151126508" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000168269500001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11350661" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref70"></a><li class="even" id="refItem70"><p class="number">70</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Donzella GA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schols D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lin SW</contrib>. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. <span class="NLM_source">Nat Med</span> 1998;4:72-77<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2Fnm0198-072" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000072249700037" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9427609" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref71"></a><li class="odd" id="refItem71"><p class="number">71</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hendrix CW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Flexner C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">MacFarland RT</contrib>, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR4 chemokine receptor, in human volunteers. <span class="NLM_source">Antimicrob Agents Chemother</span> 2000;44:1667-1673<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FAAC.44.6.1667-1673.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000087156100041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10817726" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref72"></a><li class="even" id="refItem72"><p class="number">72</p><p class="content">Schols D, Claes S, De Clercq E, et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 levels in humans. In: Programs and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, February 24–28, 2002. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2002:53. abstract.<br></p></li><a name="ref73"></a><li class="odd" id="refItem73"><p class="number">73</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">de Vreese K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kofler-Mongold V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Leutgeb C</contrib>, et al. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. <span class="NLM_source">J Virol</span> 1996;70:689-696<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r073&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1996TP52600002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r073&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8551604" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref74"></a><li class="even" id="refItem74"><p class="number">74</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zhang L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Yu W</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">He T</contrib>, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. <span class="NLM_source">Science</span> 2002;298:995-1000<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r074&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1126%2Fscience.1076185" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r074&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000178932000047" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r074&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12351674" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref75"></a><li class="odd" id="refItem75"><p class="number">75</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eckert DM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Malashkevich VN</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hong LH</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Carr PA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kim PS</contrib>. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. <span class="NLM_source">Cell</span> 1999;99:103-115<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1016%2FS0092-8674%2800%2980066-5" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000082981600012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10520998" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref76"></a><li class="even" id="refItem76"><p class="number">76</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ferrer M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kapoor TM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Strassmaier T</contrib>, et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. <span class="NLM_source">Nat Struct Biol</span> 1999;6:953-960<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r076&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F13324" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r076&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10504731" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref77"></a><li class="odd" id="refItem77"><p class="number">77</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Judice JK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Tom JY</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Huang W</contrib>, et al. Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 1997;94:13426-13430<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.94.25.13426" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1997YK82500014" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9391041" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref78"></a><li class="even" id="refItem78"><p class="number">78</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wild C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Greenwell T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matthews T</contrib>. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 1993;9:1051-1053<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1089%2Faid.1993.9.1051" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=A1993MK13000001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=8312047" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref79"></a><li class="odd" id="refItem79"><p class="number">79</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kilby JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hopkins S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Venetta TM</contrib>, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <span class="NLM_source">Nat Med</span> 1998;4:1302-1307<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1038%2F3293" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000076731000040" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9809555" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref80"></a><li class="even" id="refItem80"><p class="number">80</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kilby JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lalezari JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eron JJ</contrib>, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 2002;18:685-693[Erratum, AIDS Res Hum Retroviruses 2003;19:83.]<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r080&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1089%2F088922202760072294" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r080&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000176673100001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r080&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12167274" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref81"></a><li class="odd" id="refItem81"><p class="number">81</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Greenberg M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sista P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Miralles G</contrib>, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a phase I/II dose-ranging monotherapy trial of T-1249. <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl:S140-S140 abstract.<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r081&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000177401300129" onclick="newWindow(this.href);return false">Web of Science</a></p></li><a name="ref82"></a><li class="even" id="refItem82"><p class="number">82</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lalezari JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eron JJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Carlson M</contrib>, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <span class="NLM_source">AIDS</span> 2003;17:691-698<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r082&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1097%2F00002030-200303280-00007" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r082&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000182566700007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r082&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12646792" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref83"></a><li class="odd" id="refItem83"><p class="number">83</p><p class="content">Lalezari J, Drucker J, Demasi R, Hopkins S, Salgo M. A controlled phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir, and efavirenz in non-nucleoside naive, protease inhibitor-experienced, HIV-1-infected adults: In: Programs and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:277. abstract.<br></p></li><a name="ref84"></a><li class="even" id="refItem84"><p class="number">84</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lalezari JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Henry K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">O'Hearn M</contrib>, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. <span class="NLM_source">N Engl J Med</span> 2003;348:2175-2185<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=20&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1056%2FNEJMoa035026" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000183134700003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12637625" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref85"></a><li class="odd" id="refItem85"><p class="number">85</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lazzarin A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clotet B</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cooper D</contrib>, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. <span class="NLM_source">N Engl J Med</span> 2003;348:2186-2195<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=20&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1056%2FNEJMoa035211" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000183134700004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12773645" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref86"></a><li class="even" id="refItem86"><p class="number">86</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Greenberg M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Davison D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Jin L</contrib>, et al. In vitro antiviral activity of T-1249, a second generation fusion inhibitor. <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl:S14-S14 abstract.<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r086&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000177401300013" onclick="newWindow(this.href);return false">Web of Science</a></p></li><a name="ref87"></a><li class="odd" id="refItem87"><p class="number">87</p><p class="content">Eron J, Merigan T, Kilby M, et al. A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. In: Programs and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:47. abstract.<br></p></li><a name="ref88"></a><li class="even" id="refItem88"><p class="number">88</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wei X</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Decker JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Liu H</contrib>, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. <span class="NLM_source">Antimicrob Agents Chemother</span> 2002;46:1896-1905<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FAAC.46.6.1896-1905.2002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000175662800041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12019106" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref89"></a><li class="odd" id="refItem89"><p class="number">89</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rimsky LT</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shugars DC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matthews TJ</contrib>. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. <span class="NLM_source">J Virol</span> 1998;72:986-993<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r089&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000071440200012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r089&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=9444991" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref90"></a><li class="even" id="refItem90"><p class="number">90</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Derdeyn CA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Decker JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sfakianos JN</contrib>, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. <span class="NLM_source">J Virol</span> 2000;74:8358-8367<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.74.18.8358-8367.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000088933700018" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=10954535" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref91"></a><li class="odd" id="refItem91"><p class="number">91</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lu J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sista P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cammack N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kurtizkes D</contrib>. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl:S74-S74 abstract.<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r091&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000177401300068" onclick="newWindow(this.href);return false">Web of Science</a></p></li><a name="ref92"></a><li class="even" id="refItem92"><p class="number">92</p><p class="content">Miralles G, Lalezari J, Bellos N, et al. T-1249 demonstrates potent antiviral activity over 10-day dosing in most patients who have failed a regimen containing enfuvirtide: planned interim analysis of T1249-102, a phase I/II study. In: Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2003:63. abstract.<br></p></li><a name="ref93"></a><li class="odd" id="refItem93"><p class="number">93</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Derdeyn CA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Decker JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sfakianos JN</contrib>, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. <span class="NLM_source">J Virol</span> 2001;75:8605-8614<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FJVI.75.18.8605-8614.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000170512800027" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11507206" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref94"></a><li class="even" id="refItem94"><p class="number">94</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Reeves JD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallo SA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ahmad N</contrib>, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2002;99:16249-16254<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1073%2Fpnas.252469399" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000179783400077" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=12444251" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref95"></a><li class="odd" id="refItem95"><p class="number">95</p><p class="content">Greenberg ML, McDanal CB, Stanfield-Oakley SA, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. In: Programs and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:184. abstract.<br></p></li><a name="ref96"></a><li class="even" id="refItem96"><p class="number">96</p><p class="content">Tremblay C, Kollman C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy observed between the fusion inhibitor T-20 and a CXCR4 blocker, AMD3100. In: Programs and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30–February 4, 2000. Alexandria, Va.: Foundation for Retrovirology and Human Health, 2001:170. abstract.<br></p></li><a name="ref97"></a><li class="odd" id="refItem97"><p class="number">97</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nagashima KA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Thompson DA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rosenfield SI</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Maddon PJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dragic T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Olson WC</contrib>. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. <span class="NLM_source">J Infect Dis</span> 2001;183:1121-1125<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1086%2F319284" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000167366900019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11237840" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref98"></a><li class="lastChild even" id="refItem98"><p class="number">98</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Tremblay CL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Giguel F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kollmann C</contrib>, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. <span class="NLM_source">Antimicrob Agents Chemother</span> 2002;46:1336-1339<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=16&amp;doi=10.1056%2FNEJMra022812&amp;key=10.1128%2FAAC.46.5.1336-1339.2002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=128&amp;doi=10.1056%2FNEJMra022812&amp;key=000175100800025" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=8&amp;doi=10.1056%2FNEJMra022812&amp;key=11959565" onclick="newWindow(this.href);return false">Medline</a></p></li></ol></div></dd><dd style="display: none;" id="citedby"><div class="section"><h3>Citing Articles</h3><ol class="striped"><li class="firstChild odd"><p class="number">1</p><p class="content">Tsukasa Mizuhara, Shinya Oishi, Hiroaki Ohno, Kazuya Shimura, Masao Matsuoka, Nobutaka Fujii.  (2013) Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry</span></i> <b>21</b>:7, 2079-2087<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmc.2013.01.016" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">2</p><p class="content">Shahrukh T. Asundaria, Christophe Pannecouque, Erik Clercq, Claudiu T. Supuran, Keshav C. Patel.  (2013) Synthesis of novel biologically active methylene derivatives of sydnones. <i><span class="NLM_source">Medicinal Chemistry Research</span></i><br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/s00044-013-0567-7" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">3</p><p class="content">Henri G. Franquelim, Diana Gaspar, A. Salomé Veiga, Nuno C. Santos, Miguel A.R.B. Castanho.  (2013) Decoding distinct membrane interactions of HIV-1 fusion inhibitors using a combined atomic force and fluorescence microscopy approach. <i><span class="NLM_source">Biochimica et Biophysica Acta (BBA) - Biomembranes</span></i><br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bbamem.2013.03.006" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">4</p><p class="content">Yen-Chun Shiang, Chung-Mao Ou, Shih-Ju Chen, Ting-Yu Ou, Han-Jia Lin, Chih-Ching Huang, Huan-Tsung Chang.  (2013) Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. <i><span class="NLM_source">Nanoscale</span></i> <b>5</b>:7, 2756<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1039/c3nr33403a" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">5</p><p class="content">Szilvia Kanizsai, Ágoston Ghidán, Joseph Ongrádi, Károly Nagy.  (2012) Antiretroviral effect of 4-thio-uridylate against human immunodeficiency virus type 1. <i><span class="NLM_source">Acta Microbiologica et Immunologica Hungarica</span></i> <b>59</b>:4, 499-510<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1556/AMicr.59.2012.4.7" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">6</p><p class="content">Tsukasa Mizuhara, Shinya Oishi, Hiroaki Ohno, Kazuya Shimura, Masao Matsuoka, Nobutaka Fujii.  (2012) Structure–activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry</span></i> <b>20</b>:21, 6434-6441<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmc.2012.08.030" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">7</p><p class="content">Kenji Maeda, Debananda Das, Hirotomo Nakata, Hiroaki Mitsuya.  (2012) CCR5 inhibitors: emergence, success, and challenges. <i><span class="NLM_source">Expert Opinion on Emerging Drugs</span></i> <b>17</b>:2, 135-145<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1517/14728214.2012.673584" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">8</p><p class="content">Chie Hashimoto, Wataru Nomura, Aki Ohya, Emiko Urano, Kosuke Miyauchi, Tetsuo Narumi, Haruo Aikawa, Jun A. Komano, Naoki Yamamoto, Hirokazu Tamamura.  (2012) Evaluation of a synthetic C34 trimer of HIV-1 gp41 as AIDS vaccines. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry</span></i> <b>20</b>:10, 3287-3291<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmc.2012.03.050" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">9</p><p class="content">Sónia Troeira Henriques, David J. Craik.  (2012) Importance of the Cell Membrane on the Mechanism of Action of Cyclotides. <i><span class="NLM_source">ACS Chemical Biology</span></i>120203100030008<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1021/cb200395f" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">10</p><p class="content">Bruno Pozzetto, Olivier Delézay, Amandine Brunon-Gagneux, Hind Hamzeh-Cognasse, Frédéric Lucht, Thomas Bourlet.  (2012) Current and future microbicide approaches aimed at preventing HIV infection in women. <i><span class="NLM_source">Expert Review of Anti-infective Therapy</span></i> <b>10</b>:2, 167-183<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1586/eri.11.173" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">11</p><p class="content">Wataru Nomura, Chie Hashimoto, Aki Ohya, Kosuke Miyauchi, Emiko Urano, Tomohiro Tanaka, Tetsuo Narumi, Toru Nakahara, Jun A. Komano, Naoki Yamamoto, Hirokazu Tamamura.  (2012) A Synthetic C34 Trimer of HIV-1 gp41 Shows Significant Increase in Inhibition Potency. <i><span class="NLM_source">ChemMedChem</span></i>n/a-n/a<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/cmdc.201100542" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">12</p><p class="content">A. M. T. Martins do Canto, A. J. Palace Carvalho, J. P. Prates Ramalho, Luís M. S. Loura.  (2012) Molecular Dynamics Simulation of HIV Fusion Inhibitor T-1249: Insights on Peptide-Lipid Interaction. <i><span class="NLM_source">Computational and Mathematical Methods in Medicine</span></i> <b>2012</b>, 1-14<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1155/2012/151854" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">13</p><p class="content">H P Rang, M M Dale, J M Ritter, R J Flower, G Henderson. Antiviral drugs. In: Rang &amp; Dale's Pharmacology. Elsevier, 2012:638-648.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-0-7020-3471-8.00051-2" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">14</p><p class="content">Tsukasa Mizuhara, Shinya Oishi, Hiroaki Ohno, Kazuya Shimura, Masao Matsuoka, Nobutaka Fujii.  (2012) Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. <i><span class="NLM_source">Organic &amp; Biomolecular Chemistry</span></i> <b>10</b>:33, 6792<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1039/c2ob25904d" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">15</p><p class="content">A.M.T. Martins do Canto, A.J. Palace Carvalho, J.P. Prates Ramalho, Luís M.S. Loura.  (2011) Molecular dynamics simulations of T-20 HIV fusion inhibitor interacting with model membranes. <i><span class="NLM_source">Biophysical Chemistry</span></i> <b>159</b>:2-3, 275-286<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bpc.2011.08.001" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">16</p><p class="content">Parvesh Singh, Parul Sharma, Krishna Bisetty, Francesc J. Corcho, Juan J. Perez.  (2011) Comparative structural studies of T-20 analogues using molecular dynamics. <i><span class="NLM_source">Computational and Theoretical Chemistry</span></i> <b>974</b>:1-3, 122-132<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.comptc.2011.07.024" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">17</p><p class="content">Palanee Ammaranond, Sayompoo Sanguansittianan.  (2011) Mechanism of HIV antiretroviral drugs progress toward drug resistance. <i><span class="NLM_source">Fundamental &amp; Clinical Pharmacology</span></i>no-no<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1111/j.1472-8206.2011.01009.x" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">18</p><p class="content">Henri G. Franquelim, Pedro M. Matos, A. Salomé Veiga. HIV vs. HIV: Turning HIV-Derived Peptides into Drugs. In: Peptide Drug Discovery and Development. Wiley-VCH Verlag GmbH &amp; Co. KGaA, 2011:209-229.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/9783527636730.ch10" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">19</p><p class="content">Yan Liu, Zhuofeng Ke, Kwok Yiu Wu, Shuwen Liu, Wen-Hua Chen, Shibo Jiang, Zhi-Hong Jiang.  (2011) An Amphiphilic Conjugate Approach toward the Design and Synthesis of Betulinic Acid-Polyphenol Conjugates as Inhibitors of the HIV-1 gp41 Fusion Core Formation. <i><span class="NLM_source">ChemMedChem</span></i> <b>6</b>:9, 1654-1664<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/cmdc.201100149" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">20</p><p class="content">Szu-Cheng Kuo, Ying-Ju Chen, Yu-Ming Wang, Ming-Der Kuo, Tzyy-Rong Jinn, Wen-Shuo Chen, Yen-Chung Chang, Kuo-Lun Tung, Tzong-Yuan Wu, Szecheng J. Lo.  (2011) Cell-based analysis of Chikungunya virus membrane fusion using baculovirus-expression vectors. <i><span class="NLM_source">Journal of Virological Methods</span></i> <b>175</b>:2, 206-215<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.jviromet.2011.05.015" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">21</p><p class="content">Matthew Grant, Rafik Samuel, Robert L. Bettiker, Byungse Suh.  (2011) Antiretroviral therapy 2010 update: Current practices and controversies. <i><span class="NLM_source">Archives of Pharmacal Research</span></i> <b>34</b>:7, 1045-1053<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/s12272-011-0701-3" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">22</p><p class="content">José A. Esté. Inhibition of HIV Entry. Wiley-VCH Verlag GmbH &amp; Co. KGaA, 2011:29-50.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/9783527635955.ch2" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">23</p><p class="content">Lin Li, Suiyi Tan, Hong Lu, Lu Lu, Jie Yang, Hong Jin, Shuwen Liu, Shibo Jiang.  (2011) Combinations of 3-Hydroxyphthalic Anhydride-Modified Ovalbumin With Antiretroviral Drug-Based Microbicide Candidates Display Synergistic and Complementary Effects Against HIV-1 Infection. <i><span class="NLM_source">JAIDS Journal of Acquired Immune Deficiency Syndromes</span></i> <b>56</b>:5, 384-392<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1097/QAI.0b013e31820a4a8d" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">24</p><p class="content">SUGGESTED READINGS. In: Basic Immunology. Elsevier, 2011:239-243.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-1-4160-5569-3.50016-0" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">25</p><p class="content">Gary Frey, Jia Chen, Sophia Rits-Volloch, Michael M Freeman, Susan Zolla-Pazner, Bing Chen.  (2010) Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. <i><span class="NLM_source">Nature Structural &amp; Molecular Biology</span></i> <b>17</b>:12, 1486-1491<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1038/nsmb.1950" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">26</p><p class="content">Soumitra Basu, Adegboyega Oyelere. The Application of Recombinant DNA Technology in Medicinal Chemistry and Drug Discovery. In: Burger's Medicinal Chemistry and Drug Discovery. John Wiley &amp; Sons, Inc., 2010.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/0471266949.bmc023.pub2" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">27</p><p class="content">Henri G. Franquelim, A. Salomé Veiga, G. Weissmüller, Nuno C. Santos, Miguel A.R.B. Castanho.  (2010) Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor sifuvirtide towards phosphatidylcholine-rich rigid membranes. <i><span class="NLM_source">Biochimica et Biophysica Acta (BBA) - Biomembranes</span></i> <b>1798</b>:6, 1234-1243<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bbamem.2010.02.010" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">28</p><p class="content">Shibo Jiang, Runming Li, Lanying Du, Shuwen Liu.  (2010) Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. <i><span class="NLM_source">Protein &amp; Cell</span></i> <b>1</b>:4, 342-354<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/s13238-010-0054-6" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">29</p><p class="content">Guangyan Zhou, Dong Wu, Evan Hermel, Edina Balogh, Miriam Gochin.  (2010) Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry Letters</span></i> <b>20</b>:5, 1500-1503<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmcl.2010.01.111" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">30</p><p class="content">Yong Wang, Hong Lu, Qiang Zhu, Shibo Jiang, Yun Liao.  (2010) Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry Letters</span></i> <b>20</b>:1, 189-192<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmcl.2009.10.139" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">31</p><p class="content">V.A. Morozov, A.V. Morozov, S. Lagaye.  (2010) Short Communication: Simultaneous Substitutions of V38M and N43T-N44K in the gp41 Heptad Repeat 1 (HR1) Disrupt HIV Type 1 gPr160 Endoproteolytic Cleavage
              <sup>*</sup>. <i><span class="NLM_source">AIDS Research and Human Retroviruses</span></i> <b>26</b>:1, 73-77<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1089/aid.2009.0079" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">32</p><p class="content">WILLIAM A. PETRI, BARBARA J. MANN, CHRISTOPHER D. HUSTON. Microbial Adherence. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:15-25.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-0-443-06839-3.00002-3" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">33</p><p class="content">JAMES D. CHAPPELL, TERENCE S. DERMODY. Introduction to Viruses and Viral Diseases. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier, 2010:1905-1921.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-0-443-06839-3.00132-6" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">34</p><p class="content">J. Zhou, P. Swiderski, H. Li, J. Zhang, C. P. Neff, R. Akkina, J. J. Rossi.  (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. <i><span class="NLM_source">Nucleic Acids Research</span></i> <b>37</b>:9, 3094-3109<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1093/nar/gkp185" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">35</p><p class="content">C. B. Boschek, D. O. Apiyo, T. A. Soares, H. E. Engelmann, N. B. Pefaur, T. P. Straatsma, C. L. Baird.  (2009) Engineering an ultra-stable affinity reagent based on Top7. <i><span class="NLM_source">Protein Engineering Design and Selection</span></i> <b>22</b>:5, 325-332<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1093/protein/gzp007" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">36</p><p class="content">Gilles Peytavin, Vincent Calvez, Christine Katlama.  (2009) Les antagonistes du récepteur CCR5&nbsp;: une nouvelle classe d'antirétroviraux. <i><span class="NLM_source">Thérapie</span></i> <b>64</b>:1, 9-16<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.2515/therapie/2009006" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">37</p><p class="content">Jing Li, Xi Chen, Jinghe Huang, Shibo Jiang, Ying-Hua Chen.  (2009) Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors. <i><span class="NLM_source">Immunobiology</span></i> <b>214</b>:1, 51-60<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.imbio.2008.04.005" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">38</p><p class="content">Kenji Maeda, Debananda Das, Philip D. Yin, Kiyoto Tsuchiya, Hiromi Ogata-Aoki, Hirotomo Nakata, Rachael B. Norman, Lauren A. Hackney, Yoshikazu Takaoka, Hiroaki Mitsuya.  (2008) Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition. <i><span class="NLM_source">Journal of Molecular Biology</span></i> <b>381</b>:4, 956-974<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.jmb.2008.06.041" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">39</p><p class="content">Stephen C Harrison.  (2008) Viral membrane fusion. <i><span class="NLM_source">Nature Structural &amp;#38; Molecular Biology</span></i> <b>15</b>:7, 690-698<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1038/nsmb.1456" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">40</p><p class="content">Emmanuel Blot, Sophie Laberge-Le Couteulx, Hossein Jamali, Marie Cornic, Cécile Guillemet, Christian Duval, Marie-France Hellot, Jean-Yves Pille, Jean-Michel Picquenot, Corinne Veyret.  (2008) CxCR4 Membrane Expression in Node-Negative Breast Cancer. <i><span class="NLM_source">The Breast Journal</span></i> <b>14</b>:3, 268-274<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1111/j.1524-4741.2008.00573.x" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">41</p><p class="content">António M. T. Martins Do Canto, A. J. Palace Carvalho, J. P. Prates Ramalho, Luís M. S. Loura.  (2008) T-20 and T-1249 HIV fusion inhibitors' structure and conformation in solution: a molecular dynamics study. <i><span class="NLM_source">Journal of Peptide Science</span></i> <b>14</b>:4, 442-447<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/psc.982" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">42</p><p class="content">G. Frey, H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, B. Chen.  (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. <i><span class="NLM_source">Proceedings of the National Academy of Sciences</span></i> <b>105</b>:10, 3739-3744<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1073/pnas.0800255105" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">43</p><p class="content">LKK Tan, M Nelson.  (2008) Maraviroc: a CCR5 antagonist. <i><span class="NLM_source">Future HIV Therapy</span></i> <b>2</b>:2, 111-123<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.2217/17469600.2.2.111" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">44</p><p class="content">Jason D. Barbour, Steven G. Deeks. Clinical Implications of HIV Fitness and Virulence. In: Global HIV/AIDS Medicine. Elsevier, 2008:161-169.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-1-4160-2882-6.50019-8" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">45</p><p class="content">Erin‐Margaret Murphy, Humberto R. Jimenez, Stephen M. Smith. Current Clinical Treatments of AIDS. Elsevier, 2008:27-73.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/S1054-3589(07)56002-3" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">46</p><p class="content">Vladimir A. Morozov, Alexei V. Morozov, Dirck Schürmann, Heiko Jessen, Claudia Kücherer.  (2007) Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon®) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy. <i><span class="NLM_source">Virus Genes</span></i> <b>35</b>:2, 167-174<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/s11262-007-0098-8" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">47</p><p class="content">Stefan Pöhlmann, Jan Münch, Sheriff Aziz, Jacqueline D. Reeves, Claas Otto, George J. Leslie, Heike Hofmann, Bridget A. Puffer, Frédéric Baribaud, Andrea Marzi, Thomas Gramberg, Zhiwei Chen, Nicole Stolte, Peter Ten Haaft, Jonathan L. Heeney, Christiane Stahl-Hennig, Kerstin Mätz-Rensing, Thomas Schneider, Robert W. Doms, Frank Kirchhoff.  (2007) A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo. <i><span class="NLM_source">Virology</span></i> <b>360</b>:2, 275-285<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2006.10.020" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">48</p><p class="content">Esteban Ribera, Santiago Moreno, Pompeyo Viciana, Santiago Echevarría, Juan Flores, Adela Francés, Juan Luis Gómez-Sirvent, Juan González, José Hernández-Quero, Fernando Lozano, Josep Mallolas, Agustín Muñoz, Antonio Ocampo, Joaquín Portilla, Federico Pulido, Antonio Rivero, Jesús Santos, Vicente Soriano, Antonio Antela, Piedad Arazo, José Ramón Arribas, Manel Cervantes, Pere Domingo.  (2007) Recomendaciones españolas sobre el uso adecuado de enfuvirtida. <i><span class="NLM_source">Enfermedades Infecciosas y Microbiología Clínica</span></i> <b>25</b>:2, 131-142<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1157/13098573" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">49</p><p class="content">HP Rang, MM Dale, JM Ritter, RJ Flower. Antiviral drugs. In: Rang &amp; Dale's Pharmacology. Elsevier, 2007:679-691.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/B978-0-443-06911-6.50052-9" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">50</p><p class="content">Steven J. DeMarco, Heiko Henze, Alexander Lederer, Kerstin Moehle, Reshmi Mukherjee, Barbara Romagnoli, John A. Robinson, Federico Brianza, Frank O. Gombert, Sergio Lociuro, Christian Ludin, Jan Willem Vrijbloed, Jürg Zumbrunn, Jean-Pierre Obrecht, Daniel Obrecht, Vincent Brondani, François Hamy, Thomas Klimkait.  (2006) Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. <i><span class="NLM_source">Bioorganic &amp; Medicinal Chemistry</span></i> <b>14</b>:24, 8396-8404<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bmc.2006.09.003" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">51</p><p class="content">Fernando Arenzana-Seisdedos, Marc Parmentier.  (2006) Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. <i><span class="NLM_source">Seminars in Immunology</span></i> <b>18</b>:6, 387-403<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.smim.2006.07.007" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">52</p><p class="content">Rafik Samuel, Robert Bettiker, Byungse Suh.  (2006) Antiretroviral therapy 2006: Pharmacology, applications, and special situations. <i><span class="NLM_source">Archives of Pharmacal Research</span></i> <b>29</b>:6, 431-458<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/BF02969415" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">53</p><p class="content">Verónica Briz, Eva Poveda, Vicente Soriano.  (2006) Entrada del virus de la inmunodeficiencia humana en las células: mecanismos y posibilidades terapéuticas. <i><span class="NLM_source">Medicina Clínica</span></i> <b>126</b>:9, 341-348<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1157/13085735" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">54</p><p class="content">J MARTINGARCIA, W CAO, A VARELAROHENA, M PLASSMEYER, F GONZALEZSCARANO.  (2006) HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. <i><span class="NLM_source">Virology</span></i> <b>346</b>:1, 169-179<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2005.10.031" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">55</p><p class="content">Salomé Veiga, Yunyun Yuan, Xuqin Li, Nuno C. Santos, Gang Liu, Miguel A.R.B. Castanho.  (2006) Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. <i><span class="NLM_source">Biochimica et Biophysica Acta (BBA) - General Subjects</span></i> <b>1760</b>:1, 55-61<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.bbagen.2005.10.001" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">56</p><p class="content">Maher K. Gandhi, Rajiv Khanna.  (2005) Viruses and lymphoma. <i><span class="NLM_source">Pathology</span></i> <b>37</b>:6, 420-433<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1080/003130200500368303" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">57</p><p class="content">Saleta Sierra, Bernd Kupfer, Rolf Kaiser.  (2005) Basics of the virology of HIV-1 and its replication. <i><span class="NLM_source">Journal of Clinical Virology</span></i> <b>34</b>:4, 233-244<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.jcv.2005.09.004" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">58</p><p class="content">Wendell Weber. Receptors. CRC Press, 2005:71-108.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1201/9780849359507.ch4" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">59</p><p class="content">Zaher Merhi, Howard Minkoff.  (2005) Rapid HIV screening for women in labor. <i><span class="NLM_source">Expert Review of Molecular Diagnostics</span></i> <b>5</b>:5, 673-679<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1586/14737159.5.5.673" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">60</p><p class="content">Mauro Zaccarelli, Valerio Tozzi, Patrizia Lorenzini, Maria P Trotta, Federica Forbici, Ubaldo Visco-Comandini, Caterina Gori, Pasquale Narciso, Carlo F Perno, Andrea Antinori.  (2005) Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. <i><span class="NLM_source">AIDS</span></i> <b>19</b>:10, 1081-1089<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1097/01.aids.0000174455.01369.ad" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">61</p><p class="content">Andre J. Marozsan, Shawn E. Kuhmann, Thomas Morgan, Carolina Herrera, Enid Rivera-Troche, Serena Xu, Bahige M. Baroudy, Julie Strizki, John P. Moore.  (2005) Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). <i><span class="NLM_source">Virology</span></i> <b>338</b>:1, 182-199<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2005.04.035" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">62</p><p class="content">Paul E Sax, Elena Losina, Milton C Weinstein, A David Paltiel, Sue J Goldie, Tammy M Muccio, April D Kimmel, Hong Zhang, Kenneth A Freedberg, Rochelle P Walensky.  (2005) Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. <i><span class="NLM_source">JAIDS Journal of Acquired Immune Deficiency Syndromes</span></i> <b>39</b>:1, 69-77<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1097/01.qai.0000160406.08924.a2" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">63</p><p class="content">András Horváth, Szilvia Tőkés, Tracy Hartman, Karen Watson, Jim A. Turpin, Robert W. Buckheit, Zsolt Sebestyén, János Szöllősi, Ilona Benkő, Thomas J. Bardos, Joseph A. Dunn, László Fésüs, Ferenc D. Tóth, Janos Aradi.  (2005) Potent inhibition of HIV-1 entry by (s4dU)35. <i><span class="NLM_source">Virology</span></i> <b>334</b>:2, 214-223<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2005.01.033" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">64</p><p class="content">Bing Chen, Erik M. Vogan, Haiyun Gong, John J. Skehel, Don C. Wiley, Stephen C. Harrison.  (2005) Determining the Structure of an Unliganded and Fully Glycosylated SIV gp120 Envelope Glycoprotein. <i><span class="NLM_source">Structure</span></i> <b>13</b>:2, 197-211<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.str.2004.12.004" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">65</p><p class="content">David A. Conlon, Mark S. Jensen, Michael Palucki, Nobuyoshi Yasuda, Joann M. Um, Chunhua Yang, Frederick W. Hartner, Fuh-Rong Tsay, Yi Hsiao, Philip Pye, Nelo R. Rivera, David L. Hughes.  (2005) Stereoselective synthesis of an anti-HIV drug candidate. <i><span class="NLM_source">Chirality</span></i> <b>17</b>:S1, S149-S158<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1002/chir.20137" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">66</p><p class="content">Susan Burgin.  (2005) New Drugs, New Rashes: Update on Cutaneous Drug Reactions. <i><span class="NLM_source">Advances in Dermatology</span></i> <b>21</b>, 279-302<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.yadr.2005.03.002" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">67</p><p class="content">Ian M. Paul.  (2005) Advances in Pediatric Pharmacology, Therapeutics, and Toxicology. <i><span class="NLM_source">Advances in Pediatrics</span></i> <b>52</b>, 321-365<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.yapd.2005.03.009" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">68</p><p class="content">Stephen C. Harrison. Mechanism of Membrane Fusion by Viral Envelope Proteins. Elsevier, 2005:231-261.<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/S0065-3527(05)64007-9" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">69</p><p class="content">JC Leao, C Frezzini, S Porter.  (2004) Enfuvirtide: a new class of antiretroviral therapy for HIV infection. <i><span class="NLM_source">Oral Diseases</span></i> <b>10</b>:6, 327-329<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1111/j.1601-0825.2004.01042.x" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">70</p><p class="content">Heike Hofmann, Stefan Pöhlmann.  (2004) Cellular entry of the SARS coronavirus. <i><span class="NLM_source">Trends in Microbiology</span></i> <b>12</b>:10, 466-472<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.tim.2004.08.008" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">71</p><p class="content">Steven M. Wolinsky, Ronald S. Veazey, Kevin J. Kunstman, Per Johan Klasse, Jason Dufour, Andre J. Marozsan, Martin S. Springer, John P. Moore.  (2004) Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. <i><span class="NLM_source">Virology</span></i> <b>328</b>:1, 19-29<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2004.07.021" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">72</p><p class="content">Rajivi P. Rucker, Noorbibi K. Day, Robert A. Good, Wasu Kamchaisatian, Patricia Emmanuel, John W. Sleasman, Cathy Mayeski, Elmer Dinglasan, Soichi Haraguchi, Nutthapong Tangsinmankong.  (2004) Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. <i><span class="NLM_source">Annals of Allergy, Asthma &amp; Immunology</span></i> <b>93</b>:3, 272-276<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/S1081-1206(10)61500-1" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">73</p><p class="content">Vincent Piguet, Quentin Sattentau.  (2004) Dangerous liaisons at the virological synapse. <i><span class="NLM_source">Journal of Clinical Investigation</span></i> <b>114</b>:5, 605-610<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1172/JCI22812" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">74</p><p class="content">Vincent Piguet, Quentin Sattentau.  (2004) Dangerous liaisons at the virological synapse. <i><span class="NLM_source">Journal of Clinical Investigation</span></i> <b>114</b>:5, 605-610<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1172/JCI200422812" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">75</p><p class="content">Javier Chinen, William T Shearer.  (2004) Advances in Asthma, Allergy and Immunology Series 2004: Basic and clinical immunology. <i><span class="NLM_source">Journal of Allergy and Clinical Immunology</span></i> <b>114</b>:2, 398-405<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.jaci.2004.05.036" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">76</p><p class="content">Joseph A. Church, Michael Hughes, Jie Chen, Paul Palumbo, Lynne M. Mofenson, Patricia Delora, Elizabeth Smith, Andrew Wiznia, Elizabeth Hawkins, Prakash Sista, Coleen K. Cunningham.  (2004) Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children. <i><span class="NLM_source">The Pediatric Infectious Disease Journal</span></i> <b>23</b>:8, 713-718<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1097/01.inf.0000133045.45316.6a" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">77</p><p class="content">A. D. Lindemans.  (2004) Enfuvirtide, antiretroviraal middel met nieuw aangrijpingspunt. <i><span class="NLM_source">Medisch-Farmaceutische Mededelingen</span></i> <b>42</b>:7, 174-175<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1007/BF03058411" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">78</p><p class="content">Julian W. Tang, Deenan Pillay.  (2004) Transmission of HIV-1 drug resistance. <i><span class="NLM_source">Journal of Clinical Virology</span></i> <b>30</b>:1, 1-10<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.jcv.2003.12.002" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">79</p><p class="content">Brian Tomkowicz, Ronald G Collman.  (2004) HIV-1 entry inhibitors: closing the front door. <i><span class="NLM_source">Expert Opinion on Therapeutic Targets</span></i> <b>8</b>:2, 65-78<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1517/14728222.8.2.65" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">80</p><p class="content"> Clavel ,  François ,  Hance ,  Allan J. , .  (2004) HIV Drug Resistance. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>350</b>:10, 1023-1035<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra025195">Full Text</a><!-- ${xml_link: 10.1056%2FNEJMra025195} --></span></p></li><li class="odd"><p class="number">81</p><p class="content">Shawn E Kuhmann, John P Moore.  (2004) HIV-1 entry inhibitor entrances. <i><span class="NLM_source">Trends in Pharmacological Sciences</span></i> <b>25</b>:3, 117-120<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.tips.2004.01.005" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">82</p><p class="content">Pavel Pugach, Shawn E Kuhmann, Joann Taylor, Andre J Marozsan, Amy Snyder, Thomas Ketas, Steven M Wolinsky, Bette T Korber, John P Moore.  (2004) The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. <i><span class="NLM_source">Virology</span></i> <b>321</b>:1, 8-22<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/j.virol.2003.12.012" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">83</p><p class="content">Dimiter S. Dimitrov.  (2004) Virus entry: molecular mechanisms and biomedical applications. <i><span class="NLM_source">Nature Reviews Microbiology</span></i> <b>2</b>:2, 109-122<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1038/nrmicro817" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">84</p><p class="content">Farida Shaheen, Ronald G. Collman.  (2004) Co-receptor antagonists as HIV-1 entry inhibitors. <i><span class="NLM_source">Current Opinion in Infectious Diseases</span></i> <b>17</b>:1, 7-16<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1097/00001432-200402000-00003" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">85</p><p class="content">Stephanie J. Bissel, Clayton A. Wiley.  (2004) Human Immunodeficiency Virus Infection of the Brain: Pitfalls in Evaluating Infected/Affected Cell Populations. <i><span class="NLM_source">Brain Pathology</span></i> <b>14</b>:1, 97-108<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1111/j.1750-3639.2004.tb00503.x" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">86</p><p class="content">José AntonioIribarren, Pablo Labarga, Rafael Rubio, Juan Berenguer, JoséM. Miró, Antonio Antela, Juan González, Santiago Moreno, Julio Arrizabalaga, Lourdes Chamorro, Bonaventura Clotet, José M. Gatell, José López-Aldeguer, Esteban Martínez, Rosa Polo, Montserrat Tuset, Pompeyo Viciana, Juan Miguel Santamaría, José María Kindelán, Esteve Ribera, Ferrán Segura.  (2004) Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). <i><span class="NLM_source">Enfermedades Infecciosas y Microbiología Clínica</span></i> <b>22</b>:10, 564-642<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1016/S0213-005X(04)73163-8" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="odd"><p class="number">87</p><p class="content"> Ferranti ,  Simone ,  Menichetti ,  Francesco , .  (2003) Enfuvirtide for Prophylaxis against HIV Infection. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>349</b>:8, 815-815<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJM200308213490820">Free Full Text</a><!-- ${xml_link: 10.1056%2FNEJM200308213490820} --></span></p></li><li class="even"><p class="number">88</p><p class="content">&amp;NA;.  (2003) Novel HIV-1 therapies needed. <i><span class="NLM_source">Inpharma Weekly</span></i> <b>&amp;amp;NA;</b>:1390, 2<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.2165/00128413-200313900-00001" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="lastChild odd"><p class="number">89</p><p class="content"> Tashima ,  Karen T. ,  Carpenter ,  Charles C.J. , .  (2003) Fusion Inhibition — A Major but Costly Step Forward in the Treatment of HIV-1. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>348</b>:22, 2249-2250<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMe030042">Full Text</a><!-- ${xml_link: 10.1056%2FNEJMe030042} --></span></p></li></ol></div></dd><dd style="display: none;" class="lastChild" id="letters"><div class="letterContent" rel="10.1056/NEJMra022812"><a name="articleTop" rel="10.1056/NEJM200308213490820"></a><h1>Enfuvirtide for Prophylaxis against HIV Infection</h1><p class="citationLine"><span class="citation">N Engl J Med 2003;  349:815</span><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/349/8/">August 21, 2003</a><span class="doi">DOI:  10.1056/NEJM200308213490820</span></p><dl class="articleTabs tabPanel"><dt class="active article" id="articleTab">Article</dt><dd id="article"><div class="letter"><h3>To the Editor:</h3><p>  In their review article on a new class of drugs that inhibit human immunodeficiency virus type 1 (HIV-1) fusion, Kilby and Eron (May 29 issue)<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1</a></span> underline the virologic and immunologic benefit of enfuvirtide for drug-resistant HIV-1 infection. In our opinion, this new compound also deserves attention for antiretroviral prophylaxis because it acts before the virus enters the cell, it has activity against resistant strains of HIV when the source of infection is a patient with resistance to multiple anti-HIV drugs, and its subcutaneous route of administration may immediately ensure effective serum levels. The use of enfuvirtide in combination with other antiretroviral drugs should be considered for prophylaxis against HIV-1 infection in cases of high-risk exposure to a patient with multidrug-resistant virus.</p><div class="section section-hr"></div><div class="section section-back"><div class="section"><p>Simone Ferranti, M.D.<br>Francesco Menichetti, M.D.<br>Azienda Ospedaliera Pisana, 56124 Pisa, Italy  <br><a class="email" href="mailto:sim17one@hotmail.com"><span class="nobrWithWbr">sim17one@hotmail.<wbr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">com</span></a></p></div></div><div class="section section-back"></div><span class="moreLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/toggleRef" class="toggleRef">1 Reference</a></span><div class="letterReferences hidden"><div class="section"><ol class="striped"><a name="ref1"></a><li class="odd" id="refItem1"><p class="number">1</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kilby JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eron JJ</contrib>. Novel therapies based on mechanisms of HIV-1 cell entry. <span class="NLM_source">N Engl J Med</span> 2003;348:2228-2238<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=20&amp;doi=10.1056%2FNEJM200308213490820&amp;key=10.1056%2FNEJMra022812" onclick="newWindow(this.href);return false">Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=128&amp;doi=10.1056%2FNEJM200308213490820&amp;key=000183134700010" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=8&amp;doi=10.1056%2FNEJM200308213490820&amp;key=12773651" onclick="newWindow(this.href);return false">Medline</a></p></li></ol></div></div></div></dd><!--DiscussionReplacer_Tab_--><dt class="letters" id="lettersTab">Letters</dt><dd id="letters"><div class="letterContent" rel="10.1056/NEJM200308213490820"></div></dd></dl></div></dd></dl>
    





    


</div>


        
        





<div id="rightRail" class="">
    <!-- omit the institutional logo from the following pages -->
    
            
            <div id="institutionBox">
                
                <p>Access Provided By:<br><span class="institutionName">National University Ireland Galway  - IREL</span></p>
                
                <div style="clear: both;"></div>
            </div>
            
        
    
                        











<!-- toolsContainer -->
<div id="toolsContainer">
	<!-- toolsBox -->
	<div id="toolsBox">
		<h3>Tools</h3>
		<ul class="firstGroup">
			
			<li class="downloadPDF firstChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/pdf/10.1056/NEJMra022812" class="zone-tools-articlePdf">

					
					PDF
				</a>
			</li>
			
			
			<li class="printPage">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra022812" class="viewType-Print viewClass-Print zone-tools-articlePrint">

					
					Print
				</a>
			</li>
			
			<li class="downloadCitation lastChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showCitFormats?doi=10.1056%2FNEJMra022812" class="viewType-Layer viewClass-MediumLayer zone-tools-downloadCitation event-layer-downloadCitation-open">

					
					Download Citation
				</a>
			</li>
			
			
			
			
			
            
		</ul>
		<ul class="secondGroup">
			<li class="emailPage firstChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showMailPage?href=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;title=Novel+Therapies+Based+on+Mechanisms+of+HIV-1+Cell+Entry&amp;doi=10.1056%2FNEJMra022812" class="viewType-Layer viewClass-MediumLayer zone-tools-articleEmail">

					
					
					
					E-Mail
				</a>
			</li>
			
			<li class="savePage">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/addTag?uactid=savePage&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;doi=10.1056%2FNEJMra022812" id="savePage" class="viewType-Layer viewClass-MediumLayer zone-tools-articleSave">

					
						
						
					
					Save
				</a>
			</li>
			
			<li class="getAlert">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/addCitationAlert?context=add&amp;uactid=getAlert&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;doi=10.1056%2FNEJMra022812" id="getAlert" class="viewType-Layer viewClass-MediumLayer zone-tools-articleEmailAlert">

					
					
						
						
					
					Article Alert
				</a>
			</li>
			
			
			
			
			<li class="reprints"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/page/about-nejm/reprints" class="zone-tools-reprints">Reprints</a></li>
            <li class="permissions"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/https%3A%2F%2Fs100.copyright.com%2FAppDispatchServlet%3Fauthor%3DJ.%2BMichael%2BKilby%252C%2BJoseph%2BJ.%2BEron%26contentID%3D10.1056%252FNEJMra022812%26issueNum%3D22%26orderBeanReset%3Dtrue%26publication%3Dnejm%26publicationDate%3D05%252F29%252F2003%26publisherName%3Dmassmed%26title%3DNovel%2BTherapies%2BBased%2Bon%2BMechanisms%2Bof%2BHIV-1%2BCell%2BEntry%26volumeNum%3D348" class="zone-tools-permissions">Permissions</a></li>
			<li class="addThisIcon lastChild"><a href="http://www.addthis.com/bookmark.php" class="addthis_button zone-tools-share-click" target="_top">Share/Bookmark</a></li>
		</ul>
	</div>
	<!-- /toolsBox -->
	<!-- toolsAd -->
	<div class="toolsAd">
		

<div class="bottomAd">
    
    <div class="ad">
        














<div id="CM8ShowAd1369749603127" title="MicroTools" class="MicroTools CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTools"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369749603127&amp;format=MicroTools" border="0" alt="Advertisement" /></a></noscript>

</div>
    </div>
</div>
	</div>
	<!-- /toolsAd -->
</div>
<!-- /toolsContainer -->

                    
                









<div id="related"><div id="relatedContent"><h3>Related Articles</h3><ul><li class="firstChild lastChild"><p class="articleType"><pub-title xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" title-type="toc-heading-title" title-length="standard" title-usage="default" translit-method="none" is-translated="false" media-type="text-xml" source="default" xml:lang="EN">Correspondence</pub-title></p><p class="articleLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJM200308213490820">Enfuvirtide for Prophylaxis against HIV Infection</a></p><p class="articleDate">August 21, 2003 | S. Ferranti and F. Menichetti</p></li></ul></div><div id="topics"><h3>Topics</h3><ul><li class="firstChild lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/browse?subtopic=18_3">HIV/​AIDS</a></li></ul></div><div id="moreIn"><h3>More In</h3><ul><li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/browse?category=review">Review</a></li><li class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/348/22/">May 29, 2003</a></li></ul></div></div>

                
                    
                
        
                


<div id="rightRailAd">
<div class="bannerAdTower">
<div class="rightTower">















<div id="CM8ShowAd1369749603128" title="MedRectangle" class="MedRectangle CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MedRectangle"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369749603128&amp;format=MedRectangle" border="0" alt="Advertisement" /></a></noscript>

</div>
</div>
</div>
</div>
                



















<div id="trendsMod" class="mod pad">
    <div class="modHead">
        <h3>Trends</h3>
        
                <h4>Most Viewed (Last Week)</h4>
            
    </div>
    <div class="modBody">
        
        <ul class="csf">
            
            <li class="firstChild">
                <div class="articleType">Original Article</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMoa1214103">Prone Positioning in Severe Acute Respiratory Distress Syndrome</a>
                </div>

                
                
                        <div class="articleDate">May 20, 2013
                            
                                | C. Guérin and Others
                            
                        </div>
                    


            </li>
            
            <li>
                <div class="articleType">Original Article</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMoa1302854">A Randomized Trial of Nighttime Physician Staffing in an Intensive Care Unit</a>
                </div>

                
                
                        <div class="articleDate">May 20, 2013
                            
                                | M.P. Kerlin and Others
                            
                        </div>
                    


            </li>
            
            <li class="lastChild">
                <div class="articleType">Case Records of the Massachusetts General Hospital</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMcpc1215971">Case Challenge</a>
                </div>

                
                
                        <div class="articleDate">May 22, 2013
                            
                                | null
                            
                        </div>
                    


            </li>
            
        </ul>
    </div>
    <div class="modFoot">
        <p class="moreLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/journal-articles">More Trends</a></p>
    </div>
    

<div class="bottomAd">
    
    <div class="ad">
        














<div id="CM8ShowAd1369749603155" title="MicroTrends" class="MicroTrends CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTrends"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369749603155&amp;format=MicroTrends" border="0" alt="Advertisement" /></a></noscript>

</div>
    </div>
</div>
</div>


                
                
                        












<script type="text/javascript" src="untitled"></script><div id="nejm_jobs">  <div style="padding: 0px; margin: 0px; background: none repeat ; 0% rgb(255, 51, 0); clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-width: none; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 300px; border: 1px solid rgb(255, 51, 0); height: 1px; max-height: 1px; overflow: hidden; line-height: 1px; font-size: 1px;"></div> <!-- top red rectangle --><div id="nejm-widget" style="padding: 0px; margin: 0px; background: none repeat ; 0% rgb(255, 255, 255); clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; vertical-align: baseline; font-weight: normal; float: none; height: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 300px; border-right: 1px solid rgb(207, 207, 207); border-width: medium 1px 1px; border-style: none solid solid; border-color: -moz-use-text-color rgb(207, 207, 207) rgb(207, 207, 207); -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; line-height: 12px; font-size: 14px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px 0px 0px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;">	<a target="nejm-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; line-height: 1px; text-decoration: none;" href="http://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" style="background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: inline; margin: 0px; padding: 0px; border: medium none;" src="nejmCCID-JobsWidget.gif">	</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border-right: medium none; border-left: medium none; -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 100%; border-width: 1px medium; border-style: solid none; border-color: rgb(207, 207, 207) -moz-use-text-color;"> <!-- content --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px 0px 4px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: 'Times New Roman',Times,serif; font-size: 11px; color: rgb(51, 51, 51); font-weight: bold;">PHYSICIAN JOBS</div><div style="padding: 0px; margin: 0px 0px 0px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(102, 102, 102);">May 28, 2013</div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Chiefs/Directors/Dept. Heads</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16815/director-division-of-oncology-products-1/?query=fjwp">DIRECTOR, DIVISION OF ONCOLOGY PRODUCTS 1</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Maryland</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Hematology/Oncology</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/17041/head-and-neck-medical-oncology-associate-professor-or-professor/?query=fjwp">HEAD AND NECK MEDICAL ONCOLOGY, ASSOCIATE PROFESSOR OR PROFESSOR</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Connecticut</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Family Medicine</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16658/be-bc-family-medicine-internal-medicine-physician/?query=fjwf">BE/BC FAMILY MEDICINE/INTERNAL MEDICINE PHYSICIAN</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Kentucky</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Infectious Disease</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16256/infectious-disease-connecticut/?query=fjwf">INFECTIOUS DISEASE, CONNECTICUT</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Connecticut</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Pulmonary Disease</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16440/pulmonologist/?query=fjwf">PULMONOLOGIST</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Florida</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Surgery, Orthopedic</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16946/-450k-to-500k-for-orthopedic-surgeon-in-south-dakota/?query=fjws">$450K TO $500K FOR ORTHOPEDIC SURGEON, IN SOUTH DAKOTA</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">South Dakota</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div></div> <!-- content --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"> <!-- footer --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 5px; line-height: 5px;">&nbsp;</div><div style="padding: 0px; margin: 0px 10px 0px 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; text-align: right;"><a target="nejm-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: 'Times New Roman',Times,serif; font-size: 13px; color: rgb(255, 51, 0); text-decoration: none; text-align: right;" href="http://www.nejmcareercenter.org/?query=fjw">nejmcareercenter.org</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 9px; line-height: 9px;">&nbsp;</div></div> <!-- footer --><img style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; float: none;" src="__utm.gif" height="1" width="1"></div> <!-- nejm-widget --></div>

                    
                
                



<!-- placeholder id=null, description=N-siteWide-email -->
    <div class="emailAlert"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4138&amp;url=https%3A%2F%2Fcdf.nejm.org%2Fcampaigns%2Fgenericlp.aspx%3Fcpc%3DGMAAALLV0612C%26alertType%3Dcollection%26rcpc%3DFMAAALLV0612C%26rpromo%3DONFQSU24%26URL%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra022812&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102"><img src="AlertsAndUpdates.gif"></a>


</div>



	
      		<!-- placeholder id=null, description=N-ad-article-rightRail-1 -->
    			  <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=5017&amp;url=%2Fpage%2Fglobal-health&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102"><img src="GlobalHealth_GH4World_300x150.jpg"></a>
    		
      	
    
</div>

   




    
<script type="text/javascript">

    $("#cdfRegister").attr("href", $("#cdfRegister").attr('href') + "&url=" + window.location.href);
</script>


</div>



<div id="footer">
    <!-- placeholder id=null, description=N-ad-footer-1 -->
        <div class="rightAd"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=2078&amp;url=%2Fcontinuing-medical-education&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102"><img src="CME_300Exams_175x48.gif"></a></div>
    
    <!-- placeholder id=null, description=N-footer -->
        <dl>
  <dt class="firstChild">Content:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" tabindex="100">Home</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Ftoc%2Fnejm%2Fmedical-journal&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Current Issue</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-article-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Articles</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Issue Index</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-specialties&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Specialties &amp; Topics</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmultimedia&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Multimedia &amp; Images</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Archive 1812-1989</a></dd>
</dl>
<dl>
  <dt class="firstChild">Information For:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Authors</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Reviewers</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fproducts-and-services&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Subscribers</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Finstitution%2Fresource-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Institutions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedia&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Media</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhow-to-advertise&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Advertisers</a></dd>
</dl>
<dl>
  <dt class="firstChild">Services:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26promo%3DONFLRNA4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Subscribe</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Drenew%26promo%3DONFLRNA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Renew</a></dd> 

  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DpayBill%26promo%3DBNFLNBA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Pay Bill</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Dactivate%26promo%3DONFLNAA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Activate Subscription</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fnejm-account&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Create or Manage Account</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fnejm-alerts&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Alerts</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FshowPodcastsFeeds&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">RSS &amp; Podcasts</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Submit a Manuscript</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fmobile-applications&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Mobile</a></dd>
</dl>
<dl>
  <dt class="firstChild">Resources:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.nejmjobs.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Physician Jobs</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Freprints&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Reprints</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fpermissions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Permissions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-conference&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Medical Meetings</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fupcoming-medical-conventions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Conventions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Ffrequently-asked-questions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">FAQs</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.jwatch.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Journal Watch</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhelp&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Help</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontact-nejm&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Contact Us</a></dd>
</dl>
<dl>
  <dt class="firstChild">NEJM:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhistory-and-mission&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">About</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fproducts-and-services&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Product Information</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Feditors-and-publishers&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Editors &amp; Publishers</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2F200th-anniversary-about&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">200th Anniversary</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fterms-of-use&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Terms of Use</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fprivacy-policy&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Privacy Policy</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fcopyright-information&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Copyright</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fadvertising-policy&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" rel="nofollow">Advertising Policies</a></dd>
   <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fnejmgroup.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">NEJM Group</a></dd>
</dl>
<dl>
  <dt class="firstChild">CME:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fcme%2Fweekly-cme-program&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Weekly CME Program</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontinuing-medical-education&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Browse Weekly Exams</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontinuing-medical-education%2Fcme-info&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Your CME Activity</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DcmeWeekly%26promo%3DONF4NA1V&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Purchase Exams</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fcme%2Freview-cme&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Review CME Program</a></dd>
</dl>


<div class="socialNetworking">
  <div class="head">Follow us</div>
  <ul>
    <li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.facebook.com%2FTheNewEnglandJournalofMedicine&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="facebook"><img src="facebook.gif" alt="Facebook"></a></li>
    <li><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Ftwitter.com%2Fnejm&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="twitter"><img src="twitter.gif" alt="Twitter"></a></li>
    <li><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.youtube.com%2Fnejmvideo&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="youTube"><img src="youtube.gif" alt="YouTube"></a></li>
    <li class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fblogs.nejm.org%2Fnow%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102" class="nowNejmBlog"><img src="nowatnejm.gif" alt="Now@NEJM Blog"></a></li>
  </ul>
</div>
    
    <!-- placeholder id=null, description=N-ad-footer-2 -->
        <div class="rightAd2"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3261&amp;url=http%3A%2F%2Fwww.nejmgroup.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102"><img src="NEJMgroup.gif"></a></div>
    
</div>










<div class="corners dropDown dropDown-myNejm">


	
<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column firstChild lastChild">
		<!-- placeholder id=null, description=N-menu-MyNEJM -->
	</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>



<div class="corners dropDown dropDown-articles">



<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild">
<dt class="firstChild">Article Category</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/research">Research</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/review">Reviews</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/clinical-cases">Clinical Cases</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/perspective">Perspective</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/commentary">Commentary</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/other">Other</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-article-index">Browse all articles</a></dd>
</dl><dl class="column multimedia more lastChild">
<dt class="firstChild">Multimedia</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/medical-videos">Videos in Clinical Medicine</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/images-in-clinical-medicine">Images in Clinical Medicine</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/interactive-medical-case">Interactive Medical Cases</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/audio-summary">Weekly Audio Summaries</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia">Browse all multimedia</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


<div class="corners dropDown dropDown-issueArchive">

<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild lastChild">
<dd class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/medical-journal">This Week</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/lastweek">Last Week</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-index">Browse full index</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


<div class="corners dropDown dropDown-topics">






<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild">
    <!-- placeholder id=null, description=N-menu-selectedSpecialties -->
        <dt class="firstChild">Selected Specialties</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fcardiology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Cardiology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fendocrinology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Endocrinology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgastroenterology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Gastroenterology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgenetics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Genetics</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Foncology-hematology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Hematology/Oncology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Finfectious-disease&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Infectious Disease</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fnephrology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Nephrology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fneurology-neurosurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Neurology/Neurosurgery</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgynecology-obstetrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Obstetrics/Gynecology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fpediatrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Pediatrics</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Primary Care/Hospitalist</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fpulmonary&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Pulmonary/Critical Care</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fsurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Surgery</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fmedical-specialties&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Browse all Specialties &amp; Topics</a></dd>
    
</dl><dl class="column more lastChild">
    <!-- placeholder id=null, description=N-menu-featuredTopics -->
        <dt class="firstChild">Featured Topics</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Clinical Practice Center</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fhealth-policy-and-reform&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Health Policy and Reform</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fmedicine-and-society&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Medicine and Society</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fpage%2Fglobal-health&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Global Health</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fpage%2Finfluenza&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra022812&amp;pubId=40054102">Influenza A (H7N9)</a></dd>
    
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>



<div class="corners dropDown dropDown-authors">

<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="firstChild lastChild">
<dd class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Author Center</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Submit a Manuscript or Letter</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Track a Manuscript</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Help</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


























<script type="text/javascript">

/* <![CDATA[ */
var google_conversion_id = 1070139620;
var google_conversion_language = "en";
var google_conversion_format = "3";
var google_conversion_color = "666666";
var google_conversion_label = "_s1RCLTo-QEQ5JGk_gM";
var google_conversion_value = 0;
/* ]]> */
</script>
<script type="text/javascript" src="conversion.js">
</script><img src="untitled_001.dat" border="0" height="1" width="1">
<noscript>

<div style="display:inline;">
<img height="1" width="1" style="border-style:none;" alt="" src="http://www.googleadservices.com/pagead/conversion/1070139620/?value=0&amp;label=_s1RCLTo-QEQ5JGk_gM&amp;guid=ON&amp;script=0"/>
</div>
</noscript>







<div id="copyright">
    
    
            <p>Copyright © 2013 <a href="http://www.massmed.org/">Massachusetts Medical Society</a>. All rights reserved.</p>
        
</div>
<!--[if IE]></div><![endif]-->
<script language="javascript" src="searchbox_suggest_v1.js" type="text/javascript"></script>
<script language="javascript" type="text/javascript">

    try {
        __SLI_customisations[ __SLI_ApplicationName ][ 'ShowBrandingFooter' ] = false;
        sli_load();
    }
    catch (ex) {
        // If SLI scripts cannot be loaded, disable search hints
    }
</script>

<input id="showLayers" value="true" type="hidden">


    <!-- placeholder id=null, description=N-Layers_CONFIG -->
    <!-- placeholder id=null, description=N-ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=N-ad-promoLayer-1 -->
    
    
    

    <input id="IsInstitution" value="true" type="hidden">
    <input id="IsSubscriber" value="false" type="hidden">
    <input id="CustomerId" value="" type="hidden">
    <input id="firstAd" value="" type="hidden">
    <input id="secondAd" value="" type="hidden">




<script type="text/javascript">

        jQuery.extend(jQuery.mmsLayers.config, {
        rules: [{
                "name": "Launch Layer Ad",
                "frequency": 30,
                "showOnPage": 5,
                "enabled": false,
                "cookieName": "MarketingLaunchLayer",
                "styleClass": "launchLayer"
        },
        {
                "name": "Promo Layer Ad",
                "frequency": 42,
                "enabled": true,
                "cookieName": "PromoLayer",
                "styleClass": "promoLayer"
        },
        {
                "name": "Iperceptions - Ion Layer Ad",
                "showOnPage": 1,
                 "enabled": true,
               "test": false,
               "cookieName":"Iperceptions"
        }]
     });
    </script>

<script type="text/javascript">

    var _sf_async_config={uid:36099,domain:"nejm.org"};
    (function(){
        function loadChartbeat() {
            window._sf_endpt=(new Date()).getTime();
            var e = document.createElement('script');
            e.setAttribute('language', 'javascript');
            e.setAttribute('type', 'text/javascript');
            e.setAttribute('src',
                    (("https:" == document.location.protocol) ?
                            "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" :
                            "http://static.chartbeat.com/") +
                            "js/chartbeat.js");
            document.body.appendChild(e);
        }
        var oldonload = window.onload;
        window.onload = (typeof window.onload != 'function') ?
                loadChartbeat : function() { oldonload(); loadChartbeat(); };
    })();

</script>

<!-- Load Footer JS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-js-global-bottom -->





        
<div style="position: absolute; display: none;" id="cluetip-waitimage"></div><div style="display: none; position: absolute;" id="cluetip"><div style="z-index: 1999; opacity: 0.1; top: 1px; left: 1px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 2px; left: 2px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 3px; left: 3px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 4px; left: 4px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 5px; left: 5px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 6px; left: 6px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="position: relative; z-index: 2000;" id="cluetip-outer"><h3 id="cluetip-title"></h3><div id="cluetip-inner"></div></div><div id="cluetip-extra"></div><div id="cluetip-arrows" class="cluetip-arrows"></div></div><div id="ui-datepicker-div" class="ui-datepicker ui-widget ui-widget-content ui-helper-clearfix ui-corner-all ui-helper-hidden-accessible"></div><script src="chartbeat.js" type="text/javascript" language="javascript"></script></body>
</html>
